Clinical readouts.
Industry-sponsored Phase 2 and Phase 3 trials whose sponsors have told ClinicalTrials.gov to expect primary completion in the next six months.
Read from The ClinicalTrials.gov v2 API, restricted to industry sponsors. A primary completion date is not a readout date. Sponsors update it lazily and it commonly runs months ahead of any press release. Every row here reports what the sponsor last told the registry, and when, and is graded estimated for that reason.
Compiled . Subscribe to this lane Methodology
Confidence
750 rows shown
Week of 31 August 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bristol-Myers Squibb | As of 1 September 2026, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 5 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06730750 | |
| Clinical | H. Lundbeck | As of 21 August 2026, H. Lundbeck estimated primary completion of a Phase 3 trial in Chronic Migraine in Children, on 5 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04965675 | |
| Clinical | Merck Sharp & Dohme | As of 12 June 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Arthritis, Rheumatoid, on 5 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07176390 | |
| Clinical | ALK-Abelló | As of 20 July 2026, ALK-Abelló estimated primary completion of a Phase 3 trial in Allergic Rhinoconjunctivitis, on 6 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07060885 | |
| Clinical | CastleVax | As of 22 July 2026, CastleVax estimated primary completion of a Phase 2 trial in cOVID-19, on 6 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07215520 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 14 August 2026, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia, on 6 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07473960 |
Week of 7 September 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | ViiV Healthcare | As of 18 November 2025, ViiV Healthcare estimated primary completion of a Phase 2 trial in HIV Infections, on 9 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06741397 | |
| Clinical | Galaxy Therapeutics | As of 16 January 2026, Galaxy Therapeutics estimated primary completion of a Phase 3 trial in Intracranial Aneurysm, on 10 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05831202 | |
| Clinical | GlaxoSmithKline | As of 29 May 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in chickenpox, on 10 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06855160 | |
| Clinical | Shanghai Vitalgen BioPharma Co. | As of 31 March 2026, Shanghai Vitalgen BioPharma Co. estimated primary completion of a Phase 2 trial in Parkinson's Disease, on 10 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06480461 | |
| Clinical | NS Pharma | As of 6 March 2026, NS Pharma estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 11 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05996003 | |
| Clinical | Priovant Therapeutics | As of 12 January 2026, Priovant Therapeutics estimated primary completion of a Phase 3 trial in Uveitis, Posterior, on 11 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06431373 | |
| Clinical | Grit Biotechnology | As of 27 April 2026, Grit Biotechnology estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 13 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06144671 |
Week of 14 September 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bayer | As of 6 July 2026, Bayer estimated primary completion of a Phase 2 trial in Hemophilia A, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT03588299 | |
| Clinical | H. Lundbeck | As of 21 August 2026, H. Lundbeck estimated primary completion of a Phase 2 trial in Cushing's Disease, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06471829 | |
| Clinical | Merck Sharp & Dohme | As of 24 July 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Endometrial Neoplasms, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04634877 | |
| Clinical | Pfizer | As of 1 June 2026, Pfizer estimated primary completion of a Phase 2 trial in Obesity and Obesity-related Medical Conditions, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06924320 | |
| Clinical | Teva Branded Pharmaceutical Products R&D | As of 26 August 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 2 trial in Celiac Disease, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06807463 | |
| Clinical | Thirty Respiratory | As of 12 January 2026, Thirty Respiratory estimated primary completion of a Phase 2 trial in Pulmonary Tuberculoses, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07073638 | |
| Clinical | Wuhan YZY Biopharma Co. | As of 8 July 2026, Wuhan YZY Biopharma Co. estimated primary completion of a Phase 2 trial in Malignant Pleural Effusions, on 15 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05543330 | |
| Moved from 14 Oct 2026 | Clinical | GlaxoSmithKline | As of 17 August 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines, on 16 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07596173 |
| Clinical | Hoffmann-La Roche | As of 6 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Multiple Sclerosis, on 17 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07074886 | |
| Clinical | Vertex Pharmaceuticals Incorporated | As of 23 March 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 3 trial in Type 1 Diabetes, on 17 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06832410 | |
| Clinical | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | As of 8 September 2025, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair estimated primary completion of a Phase 3 trial in sCLC, on 18 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07145333 | |
| Clinical | Teva Branded Pharmaceutical Products R&D | As of 31 August 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 3 trial in asthma, on 19 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06664619 | |
| Clinical | Bharat Biotech International | As of 29 April 2026, Bharat Biotech International estimated primary completion of a Phase 3 trial in Active Immunisation for Chikungunya Virus Infection, on 20 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07555392 | |
| Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co. | As of 12 December 2025, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Obesity & Overweight, on 20 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07279194 |
Week of 21 September 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Cardiol Therapeutics | As of 10 September 2026, Cardiol Therapeutics estimated primary completion of a Phase 3 trial in Recurrent Pericarditis, on 21 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06708299 | |
| Clinical | BeOne Medicines | As of 2 January 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Waldenstrom Macroglobulinemia, on 22 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05952037 | |
| Clinical | ImmVira Pharma Co. | As of 8 October 2025, ImmVira Pharma Co. estimated primary completion of a Phase 2 trial in Solid Tumor, on 22 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04370587 | |
| Clinical | ModernaTX | As of 3 April 2026, ModernaTX estimated primary completion of a Phase 2 trial in Norovirus Acute Gastroenteritis, on 22 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05992935 | |
| Clinical | Pfizer | As of 20 August 2026, Pfizer estimated primary completion of a Phase 2 trial in liposarcoma, on 23 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04557449 | |
| Clinical | Sinocelltech | As of 4 September 2025, Sinocelltech estimated primary completion of a Phase 2 trial in nAMD, on 23 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06672536 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 11 July 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in obesity, on 24 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06862908 | |
| Clinical | Novartis Pharmaceuticals | As of 21 August 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus, on 24 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05798117 | |
| Clinical | AstraZeneca | As of 2 September 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Chronic Kidney Disease With High Proteinuria, on 26 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06942910 | |
| Clinical | Biogen | As of 29 January 2026, Biogen estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 27 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04961567 |
Week of 28 September 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | AstraZeneca | As of 17 June 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Gastric Cancer, on 28 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07143604 | |
| Clinical | Attralus | As of 6 May 2026, Attralus estimated primary completion of a Phase 2 trial in Amyloidosis; Systemic, on 28 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05951049 | |
| Clinical | Incyte | As of 17 August 2026, Incyte estimated primary completion of a Phase 2 trial in Cutaneous Squamous Cell Carcinoma, on 28 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05888844 | |
| Clinical | MoonLake Immunotherapeutics | As of 6 May 2026, MoonLake Immunotherapeutics estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 28 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06768671 | |
| Clinical | Ocugen | As of 31 July 2026, Ocugen estimated primary completion of a Phase 3 trial in Stargardt Disease, on 28 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05956626 | |
| Clinical | GlaxoSmithKline | As of 8 July 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Eosinophilic Granulomatosis With Polyangiitis, on 29 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05263934 | |
| Clinical | Sanofi | As of 20 May 2026, Sanofi estimated primary completion of a Phase 2 trial in asthma, on 29 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06033833 | |
| Clinical | Accro Bioscience (Suzhou) | As of 24 July 2025, Accro Bioscience (Suzhou) estimated primary completion of a Phase 2 trial in Ulcerative Colitis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07083193 | |
| Clinical | Allist Pharmaceuticals | As of 4 April 2025, Allist Pharmaceuticals estimated primary completion of a Phase 3 trial in Advanced Non-squamous Non-small-cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06416410 | |
| Clinical | Arrowhead Pharmaceuticals | As of 18 August 2026, Arrowhead Pharmaceuticals estimated primary completion of a Phase 2 trial in Hyperlipidemia; Mixed, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07223658 | |
| Clinical | AstraZeneca | As of 18 June 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05221840 | |
| Clinical | AstraZeneca | As of 1 September 2026, AstraZeneca estimated primary completion of a Phase 2 trial in dyslipidaemia, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07218900 | |
| Clinical | AstraZeneca | As of 26 June 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Hepatocellular Carcinoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05557838 | |
| Clinical | AstraZeneca | As of 14 May 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Metastatic Non-small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06417814 | |
| Clinical | Beijing Continent Pharmaceutical Co | As of 24 November 2025, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 3 trial in pneumoconiosis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05288179 | |
| Clinical | Beijing Pearl Biotechnology Limited Liability | As of 29 June 2025, Beijing Pearl Biotechnology Limited Liability estimated primary completion of a Phase 3 trial in Non-small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05989542 | |
| Clinical | BioInvent International | As of 24 April 2025, BioInvent International estimated primary completion of a Phase 2 trial in Indolent B-Cell Non-Hodgkin Lymphoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT03571568 | |
| Clinical | Biogen | As of 10 February 2026, Biogen estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04895241 | |
| Clinical | Bristol-Myers Squibb | As of 11 June 2025, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05888831 | |
| Clinical | CSPC Ouyi Pharmaceutical Co. | As of 6 May 2025, CSPC Ouyi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Major Depressive Disorder (MDD), on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06958692 | |
| Clinical | Cantex Pharmaceuticals | As of 31 March 2026, Cantex Pharmaceuticals estimated primary completion of a Phase 2 trial in glioblastoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05986851 | |
| Clinical | Chongqing Claruvis Pharmaceutical Co. | As of 22 January 2026, Chongqing Claruvis Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Upper Limb Spasticity, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06783114 | |
| Clinical | Daiichi Sankyo | As of 6 February 2026, Daiichi Sankyo estimated primary completion of a Phase 2 trial in Extensive Stage-small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06362252 | |
| Clinical | EIP Pharma | As of 8 July 2026, EIP Pharma estimated primary completion of a Phase 2 trial in Moderate to Severe Acute Ischaemic Stroke, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06987643 | |
| Clinical | EMD Serono Research & Development Institute | As of 28 May 2026, EMD Serono Research & Development Institute estimated primary completion of a Phase 2 trial in Non-Small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05882734 | |
| Clinical | EveryONE Medicines | As of 17 March 2026, EveryONE Medicines estimated primary completion of a Phase 2 trial in Pediatric SDLT CNS Disorders, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07410143 | |
| Clinical | EyeBiotech | As of 20 August 2026, EyeBiotech estimated primary completion of a Phase 3 trial in Diabetic Macular Edema (DME), on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06571045 | |
| Clinical | GlaxoSmithKline | As of 19 May 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Salmonella Infections, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06213506 | |
| Clinical | GlaxoSmithKline | As of 14 November 2025, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Alzheimer's Disease, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06079190 | |
| Clinical | GlaxoSmithKline | As of 22 June 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in cholestasis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04167358 | |
| Clinical | GlaxoSmithKline | As of 29 July 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Respiratory Syncytial Virus Infections, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06534892 | |
| Clinical | Glycomine | As of 27 February 2026, Glycomine estimated primary completion of a Phase 3 trial in Phosphomannomutase 2 Deficiency, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06892288 | |
| Clinical | Graegis Pharmaceuticals | As of 25 September 2025, Graegis Pharmaceuticals estimated primary completion of a Phase 2 trial in Radiodermatitis; Acute, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07192588 | |
| Clinical | H. Lundbeck | As of 9 March 2026, H. Lundbeck estimated primary completion of a Phase 2 trial in Congenital Adrenal Hyperplasia, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05669950 | |
| Clinical | Hansoh BioMedical R&D | As of 16 October 2024, Hansoh BioMedical R&D estimated primary completion of a Phase 3 trial in Small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06498479 | |
| Clinical | Hoffmann-La Roche | As of 13 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Carcinoma, Non-Small-Cell Lung, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04603807 | |
| Clinical | Hoffmann-La Roche | As of 17 February 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in lymphoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04980222 | |
| Clinical | ImmunityBio | As of 31 March 2026, ImmunityBio estimated primary completion of a Phase 2 trial in Non-muscle Invasive Bladder Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT02138734 | |
| Clinical | Incyte | As of 2 September 2026, Incyte estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05879822 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 15 December 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in obesity, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07000955 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 26 June 2025, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05116462 | |
| Clinical | Innovent Biopharmaceutical Technology (Hangzhou) Co. | As of 22 December 2025, Innovent Biopharmaceutical Technology (Hangzhou) Co. estimated primary completion of a Phase 3 trial in psoriasis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07265284 | |
| Clinical | J Ints Bio | As of 16 May 2025, J Ints Bio estimated primary completion of a Phase 2 trial in EGFR Mutant Advanced Non-small Cell Lung Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05394831 | |
| Clinical | Jazz Pharmaceuticals | As of 1 September 2026, Jazz Pharmaceuticals estimated primary completion of a Phase 3 trial in Gastric Neoplasms, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05152147 | |
| Clinical | Joincare Pharmaceutical Group Industry Co. | As of 20 January 2026, Joincare Pharmaceutical Group Industry Co. estimated primary completion of a Phase 2 trial in COPD (Chronic Obstructive Pulmonary Disease), on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07351734 | |
| Clinical | Kahr Bio Australia Pty | As of 20 August 2026, Kahr Bio Australia Pty estimated primary completion of a Phase 2 trial in Colorectal Cancer, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07235293 | |
| Clinical | Mirati Therapeutics | As of 23 June 2026, Mirati Therapeutics estimated primary completion of a Phase 2 trial in Advanced NSCLC, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05609578 | |
| Clinical | Novartis Pharmaceuticals | As of 15 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in KRAS G12C Mutant Solid Tumors, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05358249 | |
| Clinical | OM Pharma SA | As of 8 September 2026, OM Pharma SA estimated primary completion of a Phase 2 trial in Recurrent Wheezing, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05857930 | |
| Clinical | Shanghai JMT-Bio | As of 16 December 2024, Shanghai JMT-Bio estimated primary completion of a Phase 3 trial in Locally Advanced or Metastatic Non-squamous NSCLC, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06735391 | |
| Clinical | Shanghai Pharmaceuticals Holding Co. | As of 6 August 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Advanced Melanoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06214156 | |
| Clinical | Stamford Pharmaceuticals | As of 20 September 2024, Stamford Pharmaceuticals estimated primary completion of a Phase 2 trial in Basal Cell Carcinoma, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06344052 | |
| Clinical | SyneuRx International (Taiwan) | As of 13 September 2021, SyneuRx International (Taiwan) estimated primary completion of a Phase 3 trial in Refractory Schizophrenia, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT03094429 | |
| Clinical | Takeda | As of 6 May 2026, Takeda estimated primary completion of a Phase 2 trial in Ulcerative Colitis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06254950 | |
| Clinical | Turning Point Therapeutics | As of 4 September 2026, Turning Point Therapeutics estimated primary completion of a Phase 2 trial in Locally Advanced Solid Tumors, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT04094610 | |
| Moved from 31 Aug 2026 | Clinical | UCB Biopharma SRL | As of 11 September 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Stereotypical Prolonged Seizures, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT05077904 |
| Clinical | Umecrine Cognition | As of 28 August 2026, Umecrine Cognition estimated primary completion of a Phase 2 trial in Primary Biliary Cholangitis (PBC), on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT07304843 | |
| Clinical | UniQure Biopharma B.V. | As of 22 October 2025, UniQure Biopharma B.V. estimated primary completion of a Phase 2 trial in Amyotrophic Lateral Sclerosis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06100276 | |
| Clinical | Uniquity One | As of 11 August 2026, Uniquity One estimated primary completion of a Phase 2 trial in cOPD, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06496620 | |
| Clinical | argenx | As of 4 June 2026, argenx estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 30 September 2026. | Estimated | ClinicalTrials.gov registration: NCT06392386 | |
| Clinical | AbbVie | As of 21 August 2026, AbbVie estimated primary completion of a Phase 2 trial in Forehead Lines, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07730554 | |
| Clinical | AbbVie | As of 3 August 2026, AbbVie estimated primary completion of a Phase 3 trial in aMD, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05407636 | |
| Clinical | Actinogen Medical | As of 21 July 2026, Actinogen Medical estimated primary completion of a Phase 3 trial in Dementia Moderate, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06125951 | |
| Clinical | Acumen Pharmaceuticals | As of 27 October 2025, Acumen Pharmaceuticals estimated primary completion of a Phase 2 trial in Alzheimer Disease, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06335173 | |
| Clinical | Akeso | As of 21 January 2026, Akeso estimated primary completion of a Phase 3 trial in Biliary Tract Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06591520 | |
| Clinical | Aldena Therapeutics | As of 4 March 2026, Aldena Therapeutics estimated primary completion of a Phase 2 trial in Alopecia Areata (AA), in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06826196 | |
| Clinical | Aramis Biotechnologies | As of 4 August 2026, Aramis Biotechnologies estimated primary completion of a Phase 2 trial in influenza, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07291635 | |
| Clinical | Beijing Dongfang Biotech Co. | As of 17 September 2025, Beijing Dongfang Biotech Co. estimated primary completion of a Phase 3 trial in Type2 Diabetes Mellitus, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06257966 | |
| Clinical | Beijing InnoCare Pharma Tech Co. | As of 31 December 2025, Beijing InnoCare Pharma Tech Co. estimated primary completion of a Phase 2 trial in Plaque Psoriasis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07251998 | |
| Clinical | BioAegis Therapeutics | As of 15 June 2026, BioAegis Therapeutics estimated primary completion of a Phase 2 trial in Acute Respiratory Distress Syndrome, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05947955 | |
| Clinical | Biohaven Therapeutics | As of 13 August 2026, Biohaven Therapeutics estimated primary completion of a Phase 3 trial in Focal Epilepsy, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06309966 | |
| Clinical | CanSino Biologics | As of 6 August 2026, CanSino Biologics estimated primary completion of a Phase 2 trial in poliomyelitis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06577298 | |
| Clinical | Celldex Therapeutics | As of 25 March 2026, Celldex Therapeutics estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06455202 | |
| Clinical | Celldex Therapeutics | As of 25 March 2026, Celldex Therapeutics estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06445023 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 26 April 2024, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Non Small Cell Lung Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06300177 | |
| Clinical | Citryll BV | As of 30 January 2026, Citryll BV estimated primary completion of a Phase 2 trial in rA, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07147959 | |
| Clinical | Cocrystal Pharma | As of 17 February 2026, Cocrystal Pharma estimated primary completion of a Phase 2 trial in norovirus, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07198139 | |
| Clinical | Corcept Therapeutics | As of 16 June 2026, Corcept Therapeutics estimated primary completion of a Phase 2 trial in Amyotrophic Lateral Sclerosis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05407324 | |
| Clinical | Crinetics Pharmaceuticals | As of 19 August 2026, Crinetics Pharmaceuticals estimated primary completion of a Phase 2 trial in Cushing Syndrome, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05804669 | |
| Clinical | Debiopharm International SA | As of 24 August 2026, Debiopharm International SA estimated primary completion of a Phase 3 trial in Central Precocious Puberty, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06129539 | |
| Clinical | Disc Medicine | As of 3 August 2026, Disc Medicine estimated primary completion of a Phase 2 trial in Inflammatory Bowel Disease (IBD), in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07368972 | |
| Clinical | Eli Lilly and | As of 20 July 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 2 Diabetes, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06297603 | |
| Clinical | Eli Lilly and | As of 11 August 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Systemic Juvenile Idiopathic Arthritis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04088396 | |
| Clinical | Endeavor Biomedicines | As of 24 February 2026, Endeavor Biomedicines estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06422884 | |
| Clinical | EyePoint Pharmaceuticals | As of 3 September 2026, EyePoint Pharmaceuticals estimated primary completion of a Phase 3 trial in Wet Age Related Macular Degeneration, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06683742 | |
| Clinical | Fujian Akeylink Biotechnology Co. | As of 17 July 2026, Fujian Akeylink Biotechnology Co. estimated primary completion of a Phase 2 trial in Chronic Hepatitis B, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07709520 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 29 June 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07233070 | |
| Clinical | GEn1E Lifesciences | As of 23 June 2026, GEn1E Lifesciences estimated primary completion of a Phase 2 trial in Respiratory Distress Syndrome, Acute, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05795465 | |
| Clinical | GIE Medical | As of 25 June 2025, GIE Medical estimated primary completion of a Phase 3 trial in Esophageal Stricture, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05561114 | |
| Clinical | Gilead Sciences | As of 17 November 2025, Gilead Sciences estimated primary completion of a Phase 2 trial in Solid Tumor, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05119907 | |
| Clinical | Gilgamesh Pharmaceuticals | As of 9 February 2026, Gilgamesh Pharmaceuticals estimated primary completion of a Phase 2 trial in Major Depressive Disorder, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06236880 | |
| Clinical | Guangdong Hengrui Pharmaceutical Co. | As of 18 August 2026, Guangdong Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in cOPD, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07640451 | |
| Clinical | Housey Healthcare ULC | As of 23 April 2026, Housey Healthcare ULC estimated primary completion of a Phase 2 trial in Type 2 Diabetes, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07546929 | |
| Clinical | ImmunityBio | As of 11 May 2026, ImmunityBio estimated primary completion of a Phase 2 trial in Long COVID, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07108036 | |
| Clinical | Immunocore | As of 6 March 2026, Immunocore estimated primary completion of a Phase 2 trial in Select Advanced Solid Tumors, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04262466 | |
| Clinical | Immunovant Sciences | As of 28 August 2026, Immunovant Sciences estimated primary completion of a Phase 2 trial in Subacute Cutaneous Lupus Erythematosus, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06980805 | |
| Clinical | Industrial Farmacéutica Cantabria | As of 12 May 2026, Industrial Farmacéutica Cantabria estimated primary completion of a Phase 3 trial in Androgenetic Alopecia, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05888922 | |
| Clinical | Ingenia Therapeutics | As of 18 May 2026, Ingenia Therapeutics estimated primary completion of a Phase 2 trial in Healthy Volunteers, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07231679 | |
| Clinical | Inhatarget Therapeutics | As of 26 March 2025, Inhatarget Therapeutics estimated primary completion of a Phase 2 trial in NSCLC (advanced Non-small Cell Lung Cancer), on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06896890 | |
| Clinical | Inmunotek S.L. | As of 13 May 2025, Inmunotek S.L. estimated primary completion of a Phase 3 trial in Rhinitis, Allergic, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04898283 | |
| Clinical | Inozyme Pharma | As of 28 August 2026, Inozyme Pharma estimated primary completion of a Phase 2 trial in Gene Mutations, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06462547 | |
| Clinical | Kynexis B.V. | As of 23 June 2026, Kynexis B.V. estimated primary completion of a Phase 2 trial in Cognitive Impairment Associated With Schizophrenia (CIAS), in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07191483 | |
| Clinical | Lallemand Health Solutions | As of 18 June 2026, Lallemand Health Solutions estimated primary completion of a Phase 2 trial in Focus is on Healthy Subjects, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07246161 | |
| Clinical | Laminar Pharmaceuticals | As of 20 November 2025, Laminar Pharmaceuticals estimated primary completion of a Phase 2 trial in High-grade Glioma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04299191 | |
| Clinical | Loxo Oncology | As of 29 January 2026, Loxo Oncology estimated primary completion of a Phase 3 trial in Chronic Lymphocytic Leukemia, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04965493 | |
| Clinical | MedTrace Pharma | As of 10 August 2026, MedTrace Pharma estimated primary completion of a Phase 3 trial in Coronary Artery Disease, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05134012 | |
| Clinical | MediLink Therapeutics (Suzhou) Co. | As of 12 March 2026, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06057922 | |
| Moved from 1 Jan 2027 | Clinical | Merz Aesthetics | As of 10 September 2026, Merz Aesthetics estimated primary completion of a Phase 3 trial in Neuromuscular Agents, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07210463 |
| Clinical | Merz North America | As of 22 May 2026, Merz North America estimated primary completion of a Phase 3 trial in Neuromuscular Agents, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07122193 | |
| Clinical | Mirum Pharmaceuticals | As of 11 August 2026, Mirum Pharmaceuticals estimated primary completion of a Phase 3 trial in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06553768 | |
| Clinical | Novadip Biosciences | As of 1 April 2026, Novadip Biosciences estimated primary completion of a Phase 3 trial in Congenital Pseudarthrosis of Tibia, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07112443 | |
| Clinical | Novaliq | As of 28 July 2026, Novaliq estimated primary completion of a Phase 2 trial in Non-infectious Anterior Uveitis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07285070 | |
| Clinical | Novartis Pharmaceuticals | As of 3 July 2025, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Age-Related Macular Degeneration, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05230537 | |
| Clinical | Novo Nordisk | As of 1 September 2026, Novo Nordisk estimated primary completion of a Phase 3 trial in Heart Failure, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06200207 | |
| Clinical | Organon and | As of 17 April 2026, Organon and estimated primary completion of a Phase 3 trial in Plaque Psoriasis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05172726 | |
| Clinical | PersonGen BioTherapeutics (Suzhou) Co. | As of 6 July 2026, PersonGen BioTherapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07188610 | |
| Clinical | Pharming Technologies B.V. | As of 12 February 2026, Pharming Technologies B.V. estimated primary completion of a Phase 2 trial in Common Variable Immunodeficiency (CVID), in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06897358 | |
| Clinical | Phathom Pharmaceuticals | As of 29 June 2026, Phathom Pharmaceuticals estimated primary completion of a Phase 2 trial in Eosinophilic Esophagitis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06851559 | |
| Clinical | Philogen S.p.A. | As of 10 October 2023, Philogen S.p.A. estimated primary completion of a Phase 2 trial in glioblastoma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04443010 | |
| Clinical | Prana Therapies | As of 6 August 2026, Prana Therapies estimated primary completion of a Phase 2 trial in Mild to Moderate Asthma, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07245368 | |
| Clinical | Privo Technologies | As of 23 April 2026, Privo Technologies estimated primary completion of a Phase 3 trial in Oral Squamous Cell Carcinoma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05893888 | |
| Clinical | Qilu Pharmaceutical Co. | As of 1 December 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07256782 | |
| Clinical | RemeGen Co. | As of 17 February 2025, RemeGen Co. estimated primary completion of a Phase 2 trial in Breast Cancer, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06642545 | |
| Clinical | Research Institute of Geroprotective Technologies | As of 6 May 2026, Research Institute of Geroprotective Technologies estimated primary completion of a Phase 2 trial in Coronary Artery Disease, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07397351 | |
| Clinical | Senseye | As of 29 April 2026, Senseye estimated primary completion of a Phase 3 trial in PTSD - Post Traumatic Stress Disorder, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07280065 | |
| Clinical | Sernova Biotherapeutics | As of 25 February 2026, Sernova Biotherapeutics estimated primary completion of a Phase 2 trial in Type 1 Diabetes Mellitus, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT03513939 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 3 September 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Acute Gouty Arthritis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07706777 | |
| Clinical | Shanghai Hengrui Pharmaceutical Co. | As of 3 January 2025, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced or Metastatic Esophageal Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06474468 | |
| Clinical | Shanghai Hengrui Pharmaceutical Co. | As of 1 December 2025, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07229729 | |
| Clinical | Shanghai Hengrui Pharmaceutical Co. | As of 23 December 2025, Shanghai Hengrui Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced or Metastatic Non-small Cell Lung Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06512051 | |
| Clinical | Shanghai Huilun Pharmaceutical Co. | As of 13 July 2026, Shanghai Huilun Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Postoperative Pain, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07699601 | |
| Clinical | Shanghai Huilun Pharmaceutical Co. | As of 16 July 2026, Shanghai Huilun Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Postoperative Pain, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07709598 | |
| Clinical | Shanghai Minwei Biotechnology Co. | As of 28 August 2026, Shanghai Minwei Biotechnology Co. estimated primary completion of a Phase 2 trial in Overweight , Obesity, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07791537 | |
| Clinical | Shanghai Shengdi Pharmaceutical Co. | As of 10 September 2026, Shanghai Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Solid Tumors, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07231211 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06423885 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in HER2-positive Breast Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06316531 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 7 May 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Recurrent Glioblastoma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06598787 | |
| Clinical | Sol-Gel Technologies | As of 11 August 2026, Sol-Gel Technologies estimated primary completion of a Phase 3 trial in Gorlin Syndrome, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06050122 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 6 June 2025, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Recurrent or Metastatic Cervical Cancer, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06859775 | |
| Clinical | Suzhou Teligene | As of 28 April 2026, Suzhou Teligene estimated primary completion of a Phase 2 trial in Colorectal Cancer Metastatic, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06589830 | |
| Clinical | Taejoon Pharmaceutical Co. | As of 9 September 2026, Taejoon Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Dry Eye Syndrome (DES), in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07810972 | |
| Clinical | Taiho Oncology | As of 1 September 2026, Taiho Oncology estimated primary completion of a Phase 2 trial on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05945823 | |
| Clinical | Triveni Bio | As of 27 April 2026, Triveni Bio estimated primary completion of a Phase 2 trial in Atopic Dermatitis, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07167758 | |
| Clinical | USWM CT | As of 11 August 2026, USWM CT estimated primary completion of a Phase 2 trial in Synovial Sarcoma, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05642455 | |
| Clinical | Vanda Pharmaceuticals | As of 27 February 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 2 trial in hypertension, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT07090161 | |
| Clinical | Vyriad | As of 8 July 2026, Vyriad estimated primary completion of a Phase 2 trial in melanoma, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT04291105 | |
| Clinical | Xenon Pharmaceuticals | As of 14 May 2026, Xenon Pharmaceuticals estimated primary completion of a Phase 3 trial in Focal Onset Seizures, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT05716100 | |
| Clinical | Zhejiang Sunshine Mandi Pharmaceutical Co. | As of 9 July 2025, Zhejiang Sunshine Mandi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Acne Vulgaris, in October 2026. | Estimated | ClinicalTrials.gov registration: NCT06403501 | |
| Clinical | argenx | As of 12 January 2026, argenx estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia, on 1 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04812925 | |
| Clinical | Cerenome | As of 9 September 2026, Cerenome estimated primary completion of a Phase 2 trial in Leptomeningeal Metastasis, on 2 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07098806 | |
| Clinical | PEACHES BIOTECH | As of 10 June 2026, PEACHES BIOTECH estimated primary completion of a Phase 2 trial in sARS-CoV-2, on 2 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06684379 | |
| Clinical | Takeda | As of 1 September 2026, Takeda estimated primary completion of a Phase 3 trial in Narcolepsy Type 1 (NT1), on 2 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07363720 | |
| Clinical | Eddingpharm (Zhuhai) Co. | As of 20 May 2026, Eddingpharm (Zhuhai) Co. estimated primary completion of a Phase 2 trial in Homozygous Familial Hypercholesterolemia (HoFH), on 4 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07489209 |
Week of 5 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | ModernaTX | As of 6 May 2026, ModernaTX estimated primary completion of a Phase 2 trial in Epstein-Barr Virus Infection, on 5 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05164094 | |
| Clinical | Swedish Orphan Biovitrum | As of 30 April 2026, Swedish Orphan Biovitrum estimated primary completion of a Phase 3 trial in Primary Myelofibrosis, on 5 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03165734 | |
| Clinical | UCB Biopharma SRL | As of 11 September 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 5 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06149559 | |
| Clinical | Bristol-Myers Squibb | As of 24 March 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Idiopathic Pulmonary Fibrosis, on 6 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06003426 | |
| Moved from 15 Oct 2026 | Clinical | AstraZeneca | As of 1 September 2026, AstraZeneca estimated primary completion of a Phase 2 trial in RSV Respiratory Syncytial Virus, on 7 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07717840 |
| Clinical | Regeneron Pharmaceuticals | As of 29 May 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 7 October 2026. | Estimated | ClinicalTrials.gov registration: NCT02612454 | |
| Clinical | Hoffmann-La Roche | As of 10 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 8 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05805501 | |
| Clinical | Incyte | As of 8 July 2026, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 9 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06958211 | |
| Clinical | Incyte | As of 28 July 2026, Incyte estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, on 9 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06959225 | |
| Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co. | As of 25 September 2025, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Type 2 Diabetes, on 10 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07193459 | |
| Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co. | As of 23 June 2026, Hangzhou Zhongmei Huadong Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Plaque Psoriasis, on 10 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07357831 | |
| Clinical | Biocodex | As of 18 November 2025, Biocodex estimated primary completion of a Phase 3 trial in IBS (Irritable Bowel Syndrome), on 11 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07168434 |
Week of 12 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bristol-Myers Squibb | As of 5 September 2025, Bristol-Myers Squibb estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 12 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05372354 | |
| Clinical | Janssen Research & Development | As of 28 August 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Metastatic Castrate-sensitive Prostate Cancer, on 12 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05884398 | |
| Clinical | Regeneron Pharmaceuticals | As of 30 April 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 3 trial in Paroxysmal Nocturnal Hemoglobinuria, on 12 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05133531 | |
| Clinical | Aspa Therapeutics | As of 17 April 2026, Aspa Therapeutics estimated primary completion of a Phase 2 trial in Canavan Disease, on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04998396 | |
| Clinical | Daewoong Pharmaceutical Co. | As of 16 July 2026, Daewoong Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05389215 | |
| Clinical | GlaxoSmithKline | As of 12 November 2025, GlaxoSmithKline estimated primary completion of a Phase 2 trial in melanoma, on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06521567 | |
| Clinical | Shanghai JMT-Bio | As of 24 March 2025, Shanghai JMT-Bio estimated primary completion of a Phase 3 trial on 13 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06846437 | |
| Clinical | Hoffmann-La Roche | As of 25 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Unresectable Hepatocellular Carcinoma, on 14 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04770896 | |
| Clinical | Inozyme Pharma | As of 10 August 2026, Inozyme Pharma estimated primary completion of a Phase 3 trial in Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, on 14 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07473973 | |
| Clinical | Sanofi | As of 20 May 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Rhinosinusitis With Nasal Polyps, on 14 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06834347 | |
| Clinical | Birch BioMed | As of 4 May 2026, Birch BioMed estimated primary completion of a Phase 3 trial in Burn Scar, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06807021 | |
| Clinical | CanariaBio | As of 1 April 2026, CanariaBio estimated primary completion of a Phase 2 trial in Ovarian Neoplasm Epithelial, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05605535 | |
| Clinical | Eccogene | As of 25 June 2026, Eccogene estimated primary completion of a Phase 2 trial in Adult Obesity, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07505303 | |
| Moved from 11 Nov 2026 | Clinical | Janssen Research & Development | As of 28 August 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Ischemic Stroke; Ischemic Attack, Transient, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05702034 |
| Clinical | Novartis Pharmaceuticals | As of 1 May 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 2 trial in Metastatic Castration Resistant Prostate Cancer (mCRPC), on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06894511 | |
| Clinical | Solid Biosciences | As of 10 August 2026, Solid Biosciences estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03368742 | |
| Clinical | Suzhou Alphamab Co. | As of 17 September 2025, Suzhou Alphamab Co. estimated primary completion of a Phase 3 trial in Hemophilia A Without Inhibitor, on 15 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06569108 | |
| Clinical | Hoffmann-La Roche | As of 6 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Non-Hodgkins Lymphoma, on 16 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03533283 | |
| Clinical | Kunming Pharmaceuticals | As of 12 December 2025, Kunming Pharmaceuticals estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 18 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07279493 |
Week of 19 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bristol-Myers Squibb | As of 3 December 2025, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Systemic Lupus Erythematosus, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05617677 | |
| Clinical | Bristol-Myers Squibb | As of 2 December 2025, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Systemic Lupus Erythematosus, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05620407 | |
| Moved from 31 Oct 2026 | Clinical | Hoffmann-La Roche | As of 10 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Breast Cancer, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05852691 |
| Clinical | Incyte | As of 28 May 2026, Incyte estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06516952 | |
| Clinical | Incyte | As of 14 April 2026, Incyte estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06516965 | |
| Clinical | Pfizer | As of 4 May 2026, Pfizer estimated primary completion of a Phase 2 trial in Atopic Dermatitis, on 19 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05995964 | |
| Clinical | Biogen | As of 11 September 2026, Biogen estimated primary completion of a Phase 3 trial in Subacute Cutaneous Lupus Erythematosus, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05531565 | |
| Clinical | Bioray Laboratories | As of 21 July 2026, Bioray Laboratories estimated primary completion of a Phase 2 trial in beta-Thalassemia, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05577312 | |
| Clinical | Daiichi Sankyo | As of 12 August 2026, Daiichi Sankyo estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05875168 | |
| Clinical | LEO Pharma | As of 7 July 2026, LEO Pharma estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06311682 | |
| Clinical | Nanjing Leads Biolabs Co. | As of 11 September 2026, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Relapsed/Refractory Multiple Myeloma, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06049290 | |
| Clinical | Otsuka Pharmaceutical Development & Commercialization | As of 31 July 2026, Otsuka Pharmaceutical Development & Commercialization estimated primary completion of a Phase 3 trial in schizophrenia, on 20 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06894212 | |
| Clinical | Amgen | As of 8 January 2026, Amgen estimated primary completion of a Phase 3 trial in Sjögren's Syndrome (SS), on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06245408 | |
| Clinical | Hoffmann-La Roche | As of 23 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Progressive Multiple Sclerosis (PMS), on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03523858 | |
| Moved from 22 Sept 2026 | Clinical | Merck Sharp & Dohme | As of 20 August 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Renal Cell Carcinoma, on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05468697 |
| Clinical | Shanghai Henlius Biotech | As of 20 May 2026, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in SCLC, Extensive Stage, on 22 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06812260 | |
| Clinical | AstraZeneca | As of 2 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung, on 23 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06008093 |
Week of 26 October 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | CSL Behring | As of 23 April 2026, CSL Behring estimated primary completion of a Phase 3 trial in Congenital Hemophilia A, on 26 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06738485 | |
| Clinical | Galderma R&D | As of 12 November 2025, Galderma R&D estimated primary completion of a Phase 3 trial in Prurigo Nodularis, on 26 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04204616 | |
| Clinical | Novartis Pharmaceuticals | As of 13 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Coronary Artery Disease, on 26 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05360446 | |
| Clinical | AstraZeneca | As of 24 August 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 27 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05775159 | |
| Clinical | Akeso | As of 12 March 2025, Akeso estimated primary completion of a Phase 3 trial in NSCLC (Non-small Cell Lung Cancer), on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06617416 | |
| Clinical | Albireo, an Ipsen | As of 31 August 2026, Albireo, an Ipsen estimated primary completion of a Phase 3 trial in Biliary Atresia, on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05426733 | |
| Clinical | Boehringer Ingelheim | As of 14 May 2026, Boehringer Ingelheim estimated primary completion of a Phase 2 trial in Macular Degeneration, Age-related, on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06722157 | |
| Clinical | Hoffmann-La Roche | As of 9 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Spinal Muscular Atrophy (SMA), on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05115110 | |
| Clinical | Merck Sharp & Dohme | As of 15 May 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Carcinoma, Renal Cell, on 28 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05239728 | |
| Clinical | Merck Sharp & Dohme | As of 6 May 2026, Merck Sharp & Dohme estimated primary completion of a Phase 3 trial in Carcinoma, Renal Cell, on 29 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04736706 | |
| Clinical | Novartis Pharmaceuticals | As of 15 June 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia (ITP), on 29 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05653349 | |
| Clinical | Abbisko Therapeutics Co | As of 12 August 2024, Abbisko Therapeutics Co estimated primary completion of a Phase 2 trial in cGvHD, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06186804 | |
| Clinical | Antelope Surgical Solutions | As of 9 July 2026, Antelope Surgical Solutions estimated primary completion of a Phase 2 trial in Prostate Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06906471 | |
| Clinical | Beijing Continent Pharmaceutical Co | As of 31 March 2026, Beijing Continent Pharmaceutical Co estimated primary completion of a Phase 3 trial in Chronic Hepatitis B With Hepatic Fibrosis, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07343778 | |
| Clinical | Biotheus | As of 11 March 2025, Biotheus estimated primary completion of a Phase 2 trial in tNBC, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05918133 | |
| Clinical | CSPC Ouyi Pharmaceutical Co. | As of 6 April 2026, CSPC Ouyi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Type 2 Diabetes, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07026968 | |
| Clinical | Genzyme, a Sanofi | As of 10 July 2026, Genzyme, a Sanofi estimated primary completion of a Phase 2 trial in Gaucher Disease Type 1, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT02843035 | |
| Clinical | Innervate Radiopharmaceuticals | As of 1 July 2026, Innervate Radiopharmaceuticals estimated primary completion of a Phase 2 trial in Heart Failure, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06965621 | |
| Clinical | Innervate Radiopharmaceuticals | As of 1 July 2026, Innervate Radiopharmaceuticals estimated primary completion of a Phase 2 trial in Parkinson Disease (PD), on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07176286 | |
| Clinical | Kind Pharmaceuticals | As of 27 March 2026, Kind Pharmaceuticals estimated primary completion of a Phase 3 trial in Anemia Due to Chronic Kidney Disease, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07494409 | |
| Clinical | Laekna | As of 2 April 2026, Laekna estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04851613 | |
| Moved from 30 Nov 2026 | Clinical | Mirati Therapeutics | As of 14 August 2026, Mirati Therapeutics estimated primary completion of a Phase 2 trial in Advanced Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05853575 |
| Clinical | Natureceuticals Sdn Bhd | As of 25 August 2026, Natureceuticals Sdn Bhd estimated primary completion of a Phase 3 trial in Fatigue Related to Cancer Treatment, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07669467 | |
| Clinical | Nouscom SRL | As of 13 February 2026, Nouscom SRL estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04041310 | |
| Clinical | Pfizer | As of 3 September 2026, Pfizer estimated primary completion of a Phase 3 trial in melanoma, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04657991 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 2 March 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Advanced Unresectable or Metastatic Breast Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06679036 | |
| Clinical | Shanghai Henlius Biotech | As of 17 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Solid Tumor Cancer, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06848699 | |
| Clinical | Tyligand Pharmaceuticals (Suzhou) | As of 24 April 2026, Tyligand Pharmaceuticals (Suzhou) estimated primary completion of a Phase 2 trial in Malignant Neoplasm, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06385925 | |
| Clinical | Vertex Pharmaceuticals Incorporated | As of 10 September 2026, Vertex Pharmaceuticals Incorporated estimated primary completion of a Phase 3 trial in Cystic Fibrosis, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05444257 | |
| Clinical | Vidya Therapeutics | As of 21 July 2026, Vidya Therapeutics estimated primary completion of a Phase 2 trial in Multiple Sclerosis, on 30 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07085507 | |
| Clinical | Adagene | As of 7 January 2026, Adagene estimated primary completion of a Phase 2 trial in Advanced/Metastatic Solid Tumors, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05405595 | |
| Clinical | Amgen | As of 28 May 2026, Amgen estimated primary completion of a Phase 2 trial in MTAP-deleted NSCLC, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06593522 | |
| Clinical | Animuscure | As of 3 August 2026, Animuscure estimated primary completion of a Phase 2 trial in Sarcopenia in Elderly, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07072195 | |
| Clinical | Annexon | As of 4 May 2026, Annexon estimated primary completion of a Phase 3 trial in Geographic Atrophy, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06510816 | |
| Clinical | AskBio | As of 3 December 2025, AskBio estimated primary completion of a Phase 2 trial in Congestive Heart Failure, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05598333 | |
| Clinical | AstraZeneca | As of 17 August 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Breast Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06635447 | |
| Clinical | Avistone Biotechnology Co. | As of 21 May 2025, Avistone Biotechnology Co. estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06574347 | |
| Clinical | Changzhou Qianhong Bio-pharma Co. | As of 9 February 2026, Changzhou Qianhong Bio-pharma Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07396337 | |
| Clinical | Freya Biosciences ApS | As of 3 September 2026, Freya Biosciences ApS estimated primary completion of a Phase 2 trial in Vaginal Dysbiosis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07453069 | |
| Clinical | Genentech | As of 25 February 2026, Genentech estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06524375 | |
| Clinical | Genentech | As of 27 August 2026, Genentech estimated primary completion of a Phase 2 trial in Neoplasm Metastasis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT00781612 | |
| Clinical | Hoffmann-La Roche | As of 5 June 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03178552 | |
| Clinical | Innovent Biologics (Suzhou) Co. | As of 13 December 2024, Innovent Biologics (Suzhou) Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06083207 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 1 August 2024, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04842617 | |
| Clinical | Kadence Bio | As of 12 August 2026, Kadence Bio estimated primary completion of a Phase 2 trial in Premature Ejaculation, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07434271 | |
| Clinical | LaNova Medicines | As of 3 September 2026, LaNova Medicines estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05518045 | |
| Clinical | Longboard Pharmaceuticals | As of 12 August 2026, Longboard Pharmaceuticals estimated primary completion of a Phase 3 trial in Developmental and Epileptic Encephalopathy, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06719141 | |
| Clinical | MaaT Pharma | As of 27 December 2024, MaaT Pharma estimated primary completion of a Phase 2 trial in Transplant Complication, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05762211 | |
| Clinical | Myosin Therapeutics | As of 14 April 2026, Myosin Therapeutics estimated primary completion of a Phase 2 trial in glioblastoma (GBM), on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07185880 | |
| Clinical | NEXTGEN Bioscience | As of 13 April 2026, NEXTGEN Bioscience estimated primary completion of a Phase 2 trial in Alopecia Areata, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06104839 | |
| Clinical | Natureceuticals Sdn Bhd | As of 25 June 2026, Natureceuticals Sdn Bhd estimated primary completion of a Phase 3 trial in Fatigue Related to Cancer Treatment, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07669454 | |
| Clinical | Neurimmune | As of 19 December 2025, Neurimmune estimated primary completion of a Phase 2 trial in Amyloid Transthyretin Cardiomyopathy, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07213583 | |
| Clinical | Olema Pharmaceuticals | As of 13 August 2026, Olema Pharmaceuticals estimated primary completion of a Phase 3 trial in Breast Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06016738 | |
| Clinical | Orion Corporation, Orion Pharma | As of 14 August 2026, Orion Corporation, Orion Pharma estimated primary completion of a Phase 2 trial in Prostate Cancer Metastatic, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03436485 | |
| Clinical | Rhythm Pharmaceuticals | As of 12 February 2026, Rhythm Pharmaceuticals estimated primary completion of a Phase 2 trial in Prader-Willi Syndrome, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06772597 | |
| Clinical | Salubris Biotherapeutics | As of 22 May 2026, Salubris Biotherapeutics estimated primary completion of a Phase 2 trial in Heart Failure With Reduced Ejection Fraction, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06369298 | |
| Clinical | Sarepta Therapeutics | As of 27 February 2026, Sarepta Therapeutics estimated primary completion of a Phase 3 trial in Muscular Dystrophy, Duchenne, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT03992430 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 25 November 2024, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Breast Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06222879 | |
| Clinical | Shanghai Henlius Biotech | As of 10 March 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Carcinoma, Hepatocellular, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06742892 | |
| Clinical | Shanghai Henlius Biotech | As of 18 May 2026, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Esophageal Cancer, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06769113 | |
| Clinical | Spyre Therapeutics | As of 5 June 2026, Spyre Therapeutics estimated primary completion of a Phase 2 trial in Rheumatoid Arthritis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07148414 | |
| Clinical | TG Therapeutics | As of 21 August 2026, TG Therapeutics estimated primary completion of a Phase 3 trial in Relapsing Multiple Sclerosis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT07211633 | |
| Clinical | Takeda | As of 25 February 2026, Takeda estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT02716116 | |
| Clinical | Takeda | As of 30 March 2026, Takeda estimated primary completion of a Phase 3 trial in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT04129502 | |
| Clinical | Teva Branded Pharmaceutical Products R&D | As of 11 September 2026, Teva Branded Pharmaceutical Products R&D estimated primary completion of a Phase 3 trial in asthma, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06052267 | |
| Clinical | Topadur Pharma | As of 15 June 2026, Topadur Pharma estimated primary completion of a Phase 2 trial in Digital Ulcers in Systemic Sclerosis, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT06954597 | |
| Clinical | Viatris Innovation | As of 28 July 2026, Viatris Innovation estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05672576 | |
| Clinical | Viatris Innovation | As of 28 July 2026, Viatris Innovation estimated primary completion of a Phase 3 trial in Lupus Erythematosus, Systemic, on 31 October 2026. | Estimated | ClinicalTrials.gov registration: NCT05648500 | |
| Clinical | AbbVie | As of 14 August 2025, AbbVie estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05822752 | |
| Clinical | AbbVie | As of 9 February 2026, AbbVie estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia (CLL), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04895436 | |
| Clinical | AbbVie | As of 17 June 2026, AbbVie estimated primary completion of a Phase 2 trial in Generalized Anxiety Disorder (GAD), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06846320 | |
| Clinical | AbbVie | As of 28 October 2025, AbbVie estimated primary completion of a Phase 2 trial in High Grade Ovarian Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05456685 | |
| Clinical | Acesion Pharma | As of 12 June 2026, Acesion Pharma estimated primary completion of a Phase 2 trial in Atrial Fibrillation (AF), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07267949 | |
| Clinical | Admetsys | As of 30 July 2024, Admetsys estimated primary completion of a Phase 2 trial in hyperglycemia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT01291719 | |
| Clinical | Akeso | As of 24 June 2024, Akeso estimated primary completion of a Phase 3 trial in Gastric and Gastroesophageal Junction Adenocarcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06341335 | |
| Clinical | Alkermes | As of 24 June 2026, Alkermes estimated primary completion of a Phase 2 trial in Idiopathic Hypersomnia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06843590 | |
| Clinical | Anbogen Therapeutics | As of 24 June 2024, Anbogen Therapeutics estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05532696 | |
| Clinical | Apogee Therapeutics | As of 10 September 2026, Apogee Therapeutics estimated primary completion of a Phase 2 trial in Atopic Dermatitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06395948 | |
| Clinical | Aptose Biosciences | As of 26 August 2025, Aptose Biosciences estimated primary completion of a Phase 2 trial in Leukemia, Myeloid, Acute, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT03850574 | |
| Clinical | Arthrosi Therapeutics | As of 15 May 2026, Arthrosi Therapeutics estimated primary completion of a Phase 2 trial in gout, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07116746 | |
| Clinical | Atossa Therapeutics | As of 8 July 2026, Atossa Therapeutics estimated primary completion of a Phase 2 trial in Breast Neoplasms, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05607004 | |
| Clinical | Avistone Biotechnology Co. | As of 20 March 2026, Avistone Biotechnology Co. estimated primary completion of a Phase 2 trial in Non-Small-Cell Lung Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07336732 | |
| Clinical | BeOne Medicines | As of 9 July 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06637501 | |
| Clinical | BeOne Medicines | As of 24 August 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in Relapsed/Refractory Multiple Myeloma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04973605 | |
| Clinical | BeOne Medicines | As of 11 September 2026, BeOne Medicines estimated primary completion of a Phase 2 trial in B-cell Malignancy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05006716 | |
| Clinical | Beckley Psytech | As of 6 July 2026, Beckley Psytech estimated primary completion of a Phase 2 trial in Treatment Resistant Depression, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05660642 | |
| Clinical | BeiGene | As of 10 July 2026, BeiGene estimated primary completion of a Phase 2 trial in MSI-H/dMMR Solid Tumors, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT03736889 | |
| Clinical | BioNTech SE | As of 28 August 2026, BioNTech SE estimated primary completion of a Phase 2 trial in Colorectal Cancer Stage II, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04486378 | |
| Clinical | Bristol-Myers Squibb | As of 4 September 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06951698 | |
| Clinical | CG Oncology | As of 1 July 2026, CG Oncology estimated primary completion of a Phase 3 trial in Non Muscle Invasive Bladder Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06111235 | |
| Clinical | Calluna Pharma AS | As of 27 April 2026, Calluna Pharma AS estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06736990 | |
| Clinical | Camurus | As of 28 July 2026, Camurus estimated primary completion of a Phase 3 trial in Gastro-enteropancreatic Neuroendocrine Tumor, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05050942 | |
| Clinical | Cardiff Oncology | As of 16 June 2026, Cardiff Oncology estimated primary completion of a Phase 2 trial in Metastatic Colorectal Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06106308 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. | As of 19 September 2025, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Pancreatic Neoplasms, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06767813 | |
| Clinical | Colgate Palmolive | As of 27 May 2026, Colgate Palmolive estimated primary completion of a Phase 3 trial in Plaque, Dental, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07605338 | |
| Clinical | Corbus Pharmaceuticals | As of 3 June 2025, Corbus Pharmaceuticals estimated primary completion of a Phase 2 trial in Solid Tumor, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06603844 | |
| Clinical | DBV Technologies | As of 22 July 2026, DBV Technologies estimated primary completion of a Phase 3 trial in allergy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07003919 | |
| Clinical | Eli Lilly and | As of 12 May 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 1 Diabetes, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06914895 | |
| Clinical | Eli Lilly and | As of 1 May 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Acute Pain, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07511816 | |
| Clinical | Eli Lilly and | As of 13 July 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07215312 | |
| Clinical | Eli Lilly and | As of 20 July 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in obesity, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06662383 | |
| Clinical | Eli Lilly and | As of 17 February 2026, Eli Lilly and estimated primary completion of a Phase 3 trial in Type 1 Diabetes, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06962280 | |
| Clinical | Eli Lilly and | As of 29 September 2025, Eli Lilly and estimated primary completion of a Phase 3 trial in oSA, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06649045 | |
| Clinical | Epygenix | As of 21 August 2026, Epygenix estimated primary completion of a Phase 3 trial in Lennox Gastaut Syndrome, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05066217 | |
| Clinical | Erasca | As of 22 June 2026, Erasca estimated primary completion of a Phase 2 trial in Advanced or Metastatic Solid Tumors, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04866134 | |
| Clinical | Ferrer Internacional | As of 15 October 2025, Ferrer Internacional estimated primary completion of a Phase 2 trial in Progressive Supranuclear Palsy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06355531 | |
| Clinical | Forge Biologics | As of 20 November 2025, Forge Biologics estimated primary completion of a Phase 2 trial in Krabbe Disease, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05739643 | |
| Clinical | Forge Biologics | As of 2 June 2026, Forge Biologics estimated primary completion of a Phase 2 trial in Krabbe Disease, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04693598 | |
| Clinical | Immunic | As of 23 February 2026, Immunic estimated primary completion of a Phase 3 trial in Multiple Sclerosis, Relapsing-Remitting, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05201638 | |
| Clinical | Immunic | As of 23 February 2026, Immunic estimated primary completion of a Phase 3 trial in Multiple Sclerosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05134441 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 12 March 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Local Analgesia Via Nerve Block, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06529432 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 5 August 2024, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in HER2-expressing Advanced Solid Tumors, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06015048 | |
| Clinical | KeyBioscience | As of 19 February 2025, KeyBioscience estimated primary completion of a Phase 2 trial in Osteoarthritis in the Knee, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06833749 | |
| Clinical | Kiora Pharmaceuticals | As of 9 September 2026, Kiora Pharmaceuticals estimated primary completion of a Phase 2 trial in Macular Edema, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06825702 | |
| Clinical | LG Chem | As of 3 July 2025, LG Chem estimated primary completion of a Phase 3 trial in diphtheria, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06947499 | |
| Clinical | Lynk Pharmaceuticals Co. | As of 20 November 2025, Lynk Pharmaceuticals Co. estimated primary completion of a Phase 3 trial in Ankylosing Spondylitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07237568 | |
| Clinical | ML Bio Solutions | As of 21 July 2026, ML Bio Solutions estimated primary completion of a Phase 2 trial in lGMD2I, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04800874 | |
| Clinical | MediLink Therapeutics (Suzhou) Co. | As of 26 November 2025, MediLink Therapeutics (Suzhou) Co. estimated primary completion of a Phase 2 trial in nSCLC, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06107686 | |
| Clinical | Medicure | As of 16 October 2025, Medicure estimated primary completion of a Phase 3 trial in Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT04706013 | |
| Clinical | NeuShen Therapeutics | As of 13 April 2026, NeuShen Therapeutics estimated primary completion of a Phase 2 trial in schizophrenia(Acute), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07521683 | |
| Clinical | NewAmsterdam Pharma | As of 9 April 2026, NewAmsterdam Pharma estimated primary completion of a Phase 2 trial in dyslipidemias, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06496243 | |
| Clinical | NewAmsterdam Pharma | As of 4 June 2024, NewAmsterdam Pharma estimated primary completion of a Phase 3 trial in Atherosclerotic Cardiovascular Disease, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05202509 | |
| Clinical | Nuance Hearing | As of 15 December 2025, Nuance Hearing estimated primary completion of a Phase 3 trial in Hearing Loss Mixed, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07282028 | |
| Clinical | Pacira Pharmaceuticals | As of 25 August 2026, Pacira Pharmaceuticals estimated primary completion of a Phase 2 trial in Osteoarthritis (OA) of the Knee, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06884865 | |
| Clinical | Pharmazz | As of 31 December 2025, Pharmazz estimated primary completion of a Phase 2 trial in Hypoxic-Ischemic Encephalopathy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05514340 | |
| Clinical | Pharming Technologies B.V. | As of 13 February 2026, Pharming Technologies B.V. estimated primary completion of a Phase 2 trial in Primary Immunodeficiency Disorders (PIDs), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06549114 | |
| Moved from 30 Aug 2026 | Clinical | ReCode Therapeutics | As of 19 August 2026, ReCode Therapeutics estimated primary completion of a Phase 2 trial in Cystic Fibrosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06237335 |
| Clinical | Reunion Neuroscience | As of 24 August 2026, Reunion Neuroscience estimated primary completion of a Phase 2 trial in Adjustment Disorder, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07002034 | |
| Clinical | SK Life Science | As of 9 September 2026, SK Life Science estimated primary completion of a Phase 3 trial in Partial Epilepsy, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05067634 | |
| Clinical | Sandoz | As of 29 May 2026, Sandoz estimated primary completion of a Phase 3 trial in Relapsing Multiple Sclerosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06847724 | |
| Clinical | Scholar Rock | As of 1 September 2026, Scholar Rock estimated primary completion of a Phase 3 trial in Spinal Muscular Atrophy, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05626855 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 31 August 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Primary Aldosteronism, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07470983 | |
| Clinical | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co. | As of 27 March 2026, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co. estimated primary completion of a Phase 2 trial in Seasonal Allergic Rhinitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07398859 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Head and Neck Squamous Cell Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06668961 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 17 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Nasopharyngeal Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06118333 | |
| Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co. | As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06448312 | |
| Clinical | Sinovac Biotech Co. | As of 10 August 2026, Sinovac Biotech Co. estimated primary completion of a Phase 3 trial in Epidemic Meningitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07505888 | |
| Clinical | Stemline Therapeutics | As of 7 May 2026, Stemline Therapeutics estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05596409 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 9 January 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Malignant Solid Tumors, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06737731 | |
| Clinical | Suzhou Zelgen Biopharmaceuticals Co. | As of 5 January 2026, Suzhou Zelgen Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 1 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05584800 | |
| Clinical | Tyra Biosciences | As of 12 January 2026, Tyra Biosciences estimated primary completion of a Phase 2 trial in Locally Advanced Urothelial Carcinoma, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT05544552 | |
| Clinical | Vir Biotechnology | As of 16 January 2026, Vir Biotechnology estimated primary completion of a Phase 2 trial in Viral Hepatitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07142811 | |
| Clinical | Waterstone Pharmaceutical (Wuhan) Co. | As of 26 November 2025, Waterstone Pharmaceutical (Wuhan) Co. estimated primary completion of a Phase 3 trial in hyperkalemia, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07251309 | |
| Clinical | Wooshin Labottach Co. | As of 26 January 2026, Wooshin Labottach Co. estimated primary completion of a Phase 3 trial in Nail Psoriasis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT07029516 | |
| Clinical | Xentria | As of 21 August 2026, Xentria estimated primary completion of a Phase 2 trial in Pulmonary Sarcoidosis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06169397 | |
| Clinical | Zura Bio | As of 30 June 2026, Zura Bio estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa (HS), in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06993610 | |
| Clinical | argenx | As of 25 September 2025, argenx estimated primary completion of a Phase 2 trial in dermatomyositis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06284954 | |
| Clinical | medac | As of 27 August 2025, medac estimated primary completion of a Phase 3 trial in Moderate to Severe Atopic Dermatitis, in November 2026. | Estimated | ClinicalTrials.gov registration: NCT06239311 |
Week of 2 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | AstraZeneca | As of 29 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Cutaneous Lupus Erythematosus, on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06015737 | |
| Clinical | Bristol-Myers Squibb | As of 4 September 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06951711 | |
| Clinical | GlaxoSmithKline | As of 26 May 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Neoplasms, Rectal, on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05723562 | |
| Clinical | Keymed Biosciences Co. | As of 9 April 2026, Keymed Biosciences Co. estimated primary completion of a Phase 2 trial in Chronic Spontaneous Urticaria (CSU), on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07166211 | |
| Clinical | Regeneron Pharmaceuticals | As of 10 February 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in melanoma, on 2 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06190951 | |
| Clinical | Novartis Pharmaceuticals | As of 20 July 2026, Novartis Pharmaceuticals estimated primary completion of a Phase 3 trial in Chronic Spontaneous Urticaria, on 3 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05677451 | |
| Clinical | CMG Pharmaceutical Co. | As of 15 January 2026, CMG Pharmaceutical Co. estimated primary completion of a Phase 3 trial in dyslipidemia, on 4 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06772168 | |
| Clinical | Genzyme, a Sanofi | As of 17 December 2025, Genzyme, a Sanofi estimated primary completion of a Phase 3 trial in hemophilia, on 5 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03754790 | |
| Clinical | Incyte | As of 25 June 2026, Incyte estimated primary completion of a Phase 2 trial in B-Cell Malignancies, on 5 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04509700 | |
| Clinical | Merck Sharp & Dohme | As of 19 February 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Hodgkin Lymphoma, on 6 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03407144 | |
| Clinical | Sanofi | As of 2 June 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Rhinosinusitis With Nasal Polyps, on 6 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06834360 |
Week of 9 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Bio-Thera Solutions | As of 13 August 2025, Bio-Thera Solutions estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 9 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06376136 | |
| Clinical | GlaxoSmithKline | As of 15 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Lung Cancer, Non-Small Cell, on 9 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05565378 | |
| Clinical | Gan & Lee Pharmaceuticals. | As of 25 November 2025, Gan & Lee Pharmaceuticals. estimated primary completion of a Phase 3 trial in diabetes, on 10 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07165223 | |
| Clinical | HELP Therapeutics Co. | As of 10 February 2026, HELP Therapeutics Co. estimated primary completion of a Phase 2 trial in Heart Failure, on 10 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06340048 | |
| Clinical | AstraZeneca | As of 30 July 2026, AstraZeneca estimated primary completion of a Phase 3 trial in Breast Cancer; HER2-positive; Metastatic, on 11 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04784715 | |
| Clinical | Precigen | As of 23 April 2026, Precigen estimated primary completion of a Phase 2 trial in Cervical Cancer, on 11 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06157151 | |
| Clinical | Qilu Pharmaceutical Co. | As of 2 February 2026, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Heavy Menstrual Bleeding, on 12 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06671548 | |
| Clinical | AstraZeneca | As of 27 May 2026, AstraZeneca estimated primary completion of a Phase 2 trial in B-cell Acute Lymphoblastic Leukemia (B-ALL), on 13 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06137118 | |
| Clinical | Hoffmann-La Roche | As of 1 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 3 trial in Breast Cancer, on 13 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05646862 | |
| Clinical | Regeneron Pharmaceuticals | As of 2 July 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 13 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04626635 | |
| Clinical | Regeneron Pharmaceuticals | As of 17 June 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Overweight or Obesity, on 13 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07431086 | |
| Clinical | PolyActiva Pty | As of 8 July 2026, PolyActiva Pty estimated primary completion of a Phase 2 trial in Glaucoma, Open-Angle, on 15 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06964191 |
Week of 16 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Merck Sharp & Dohme | As of 20 January 2026, Merck Sharp & Dohme estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa, on 16 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06956235 | |
| Clinical | UCB Biopharma SRL | As of 31 July 2026, UCB Biopharma SRL estimated primary completion of a Phase 3 trial in Generalized Myasthenia Gravis, on 16 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06055959 | |
| Clinical | AstraZeneca | As of 29 July 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Gastric Cancer, on 17 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06219941 | |
| Clinical | Bristol-Myers Squibb | As of 1 April 2026, Bristol-Myers Squibb estimated primary completion of a Phase 3 trial in Sjögren's Syndrome, on 18 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05946941 | |
| Clinical | CSL Behring | As of 11 May 2026, CSL Behring estimated primary completion of a Phase 3 trial in Complex Cardiovascular Surgery With Cardiopulmonary Bypass, on 18 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07094087 | |
| Clinical | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | As of 10 June 2026, Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair estimated primary completion of a Phase 3 trial in Prostate Cancer, on 18 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03348670 | |
| Moved from 26 Aug 2026 | Clinical | Hoffmann-La Roche | As of 4 September 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Duchenne Muscular Dystrophy, on 18 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06450639 |
| Clinical | ToLymph | As of 6 March 2026, ToLymph estimated primary completion of a Phase 2 trial in Carcinoma, Non-Small-Cell Lung Cancer (NSCLC), on 18 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06693336 | |
| Clinical | Hoffmann-La Roche | As of 12 August 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Alzheimer's Disease, on 19 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06402838 | |
| Clinical | Janssen Research & Development | As of 28 August 2026, Janssen Research & Development estimated primary completion of a Phase 2 trial in Dermatitis, Atopic, on 19 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07230860 | |
| Clinical | Incyte | As of 7 July 2026, Incyte estimated primary completion of a Phase 2 trial in Moderate to Severe Asthma, on 20 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05851443 | |
| Clinical | Skye Bioscience | As of 14 January 2026, Skye Bioscience estimated primary completion of a Phase 2 trial in obesity, on 20 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06577090 | |
| Clinical | Changchun GeneScience Pharmaceutical Co. | As of 2 October 2025, Changchun GeneScience Pharmaceutical Co. estimated primary completion of a Phase 3 trial in hyperprolactinemia, on 21 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07124221 | |
| Clinical | Haisco Pharmaceutical Group Co. | As of 28 May 2026, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Pain After Surgery, on 22 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07533786 | |
| Clinical | Shanghai Henlius Biotech | As of 24 November 2025, Shanghai Henlius Biotech estimated primary completion of a Phase 2 trial in Nasopharyngeal Carcinoma (NPC), on 22 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06839066 |
Week of 23 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | GlaxoSmithKline | As of 29 May 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in chickenpox, on 23 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06693895 | |
| Clinical | GlaxoSmithKline | As of 22 May 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in Neoplasms, Colon, on 23 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06567782 | |
| Moved from 11 Dec 2026 | Clinical | GlaxoSmithKline | As of 8 September 2026, GlaxoSmithKline estimated primary completion of a Phase 3 trial in Diphtheria-Tetanus-acellular Pertussis Vaccines, on 23 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07596199 |
| Clinical | AstraZeneca | As of 23 February 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Metastatic Prostate Cancer, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06267729 | |
| Clinical | CanSino Biologics | As of 5 August 2026, CanSino Biologics estimated primary completion of a Phase 2 trial in Streptococcus Pneumoniae Infection, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07600983 | |
| Clinical | HTA Co. | As of 10 July 2025, HTA Co. estimated primary completion of a Phase 3 trial in NETS Ga68 Lu177, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07057622 | |
| Clinical | Karuna Therapeutics, Inc., a Bristol Myers Squibb | As of 26 August 2026, Karuna Therapeutics, Inc., a Bristol Myers Squibb estimated primary completion of a Phase 3 trial in Alzheimer Disease, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06585787 | |
| Clinical | Tectonic Therapeutic | As of 7 July 2026, Tectonic Therapeutic estimated primary completion of a Phase 2 trial in Pulmonary Hypertension, on 24 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06616974 | |
| Clinical | Beijing InnoCare Pharma Tech Co. | As of 8 September 2025, Beijing InnoCare Pharma Tech Co. estimated primary completion of a Phase 3 trial in Atopic Dermatitis, on 25 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06775860 | |
| Clinical | Shaanxi Micot Pharmaceutical Technology Co. | As of 1 October 2025, Shaanxi Micot Pharmaceutical Technology Co. estimated primary completion of a Phase 3 trial in Secondary Hyperparathyroidism, Chronic Kidney Disease, on 26 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07122401 | |
| Clinical | Tesaro | As of 3 September 2025, Tesaro estimated primary completion of a Phase 3 trial in neoplasms, on 26 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03981796 | |
| Clinical | Hoffmann-La Roche | As of 7 July 2026, Hoffmann-La Roche estimated primary completion of a Phase 2 trial in Type 2 Diabetes Mellitus, on 27 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07112872 | |
| Clinical | Haisco Pharmaceutical Group Co. | As of 28 October 2024, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Non-cystic Fibrosis Bronchiectasis, on 28 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06660992 | |
| Clinical | TrueBinding | As of 23 April 2026, TrueBinding estimated primary completion of a Phase 2 trial in Parkinson's Disease (PD), on 28 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06773962 | |
| Clinical | Pfizer | As of 9 July 2026, Pfizer estimated primary completion of a Phase 3 trial in Menstrual Migraine, on 29 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06641466 |
Week of 30 November 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | AUG Therapeutics | As of 1 May 2026, AUG Therapeutics estimated primary completion of a Phase 3 trial in Leukocyte Adhesion Deficiency, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05462587 | |
| Clinical | Amgen | As of 28 May 2026, Amgen estimated primary completion of a Phase 2 trial in Advanced MTAP-null Solid Tumors, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05094336 | |
| Clinical | Arvinas | As of 19 August 2026, Arvinas estimated primary completion of a Phase 2 trial in KRAS G12D Mutation, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07023731 | |
| Clinical | AstraZeneca | As of 12 May 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07081633 | |
| Clinical | Aura Biosciences | As of 13 March 2026, Aura Biosciences estimated primary completion of a Phase 2 trial in Eye Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06643884 | |
| Clinical | Bavarian Nordic | As of 8 April 2026, Bavarian Nordic estimated primary completion of a Phase 2 trial in monkeypox (Mpox), on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07199569 | |
| Clinical | BeyondBio | As of 10 March 2025, BeyondBio estimated primary completion of a Phase 2 trial in Locally Advanced or Metastatic Pancreatic Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03579836 | |
| Clinical | BeyondBio | As of 10 March 2025, BeyondBio estimated primary completion of a Phase 2 trial in Metastatic Colorectal Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05093907 | |
| Clinical | BioAge Labs | As of 10 September 2026, BioAge Labs estimated primary completion of a Phase 2 trial in Obesity and Cardiovascular Risk, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07656727 | |
| Clinical | Celgene | As of 29 November 2024, Celgene estimated primary completion of a Phase 2 trial in Multiple Myeloma, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT03989414 | |
| Clinical | Cytopeutics Sdn. Bhd. | As of 2 January 2026, Cytopeutics Sdn. Bhd. estimated primary completion of a Phase 3 trial in Acute Ischemic Stroke, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06129175 | |
| Clinical | Genentech | As of 10 September 2026, Genentech estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT04302025 | |
| Clinical | Gritgen Therapeutics Co. | As of 9 December 2025, Gritgen Therapeutics Co. estimated primary completion of a Phase 3 trial in Hemophilia A, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06833983 | |
| Clinical | Immunocore | As of 28 January 2026, Immunocore estimated primary completion of a Phase 2 trial in cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06840119 | |
| Clinical | InventisBio Co. | As of 31 March 2026, InventisBio Co. estimated primary completion of a Phase 3 trial in Breast Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06954961 | |
| Clinical | ModernaTX | As of 15 December 2025, ModernaTX estimated primary completion of a Phase 2 trial in Glycogen Storage Disease, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05095727 | |
| Clinical | Mundipharma Research | As of 14 May 2026, Mundipharma Research estimated primary completion of a Phase 2 trial in Chronic Pulmonary Aspergillosis, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06794554 | |
| Clinical | Mylan Pharmaceuticals | As of 26 January 2026, Mylan Pharmaceuticals estimated primary completion of a Phase 2 trial in contraception, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07365904 | |
| Clinical | OncoC4 | As of 22 May 2026, OncoC4 estimated primary completion of a Phase 2 trial in Metastatic Castration-resistant Prostate Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05682443 | |
| Clinical | OriCell Therapeutics Co. | As of 31 May 2024, OriCell Therapeutics Co. estimated primary completion of a Phase 2 trial in Relapsed and/or Refractory Multiple Myeloma, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06182696 | |
| Clinical | Pharming Technologies B.V. | As of 6 May 2026, Pharming Technologies B.V. estimated primary completion of a Phase 3 trial in aPDS, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT05438407 | |
| Clinical | Ranok Therapeutics (Hangzhou) Co. | As of 24 December 2025, Ranok Therapeutics (Hangzhou) Co. estimated primary completion of a Phase 2 trial in KRAS G12D Mutations, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07303465 | |
| Clinical | Sanofi | As of 6 November 2025, Sanofi estimated primary completion of a Phase 3 trial in Immune Thrombocytopenia, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07216079 | |
| Clinical | Saol Therapeutics | As of 25 August 2026, Saol Therapeutics estimated primary completion of a Phase 3 trial in Osteoarthritis Knee Pain, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07226258 | |
| Clinical | Shanghai JMT-Bio | As of 18 August 2026, Shanghai JMT-Bio estimated primary completion of a Phase 2 trial in Unresectable Locally Advanced or Metastatic Melanoma, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07280832 | |
| Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co. | As of 8 May 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in HER2-positive Breast Cancer, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06968585 | |
| Clinical | Taisho Pharmaceutical Co. | As of 15 May 2026, Taisho Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Hyperphosphatemia Patients on Hemodialysis, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07548840 | |
| Clinical | Takeda | As of 15 July 2026, Takeda estimated primary completion of a Phase 2 trial in Idiopathic Hypersomnia, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06812078 | |
| Clinical | Takeda | As of 20 August 2026, Takeda estimated primary completion of a Phase 2 trial in Narcolepsy Type 2, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06952699 | |
| Clinical | UniQure Biopharma B.V. | As of 24 August 2026, UniQure Biopharma B.V. estimated primary completion of a Phase 2 trial in Mesial Temporal Lobe Epilepsy, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT06063850 | |
| Clinical | Verdiva Bio Dev | As of 4 August 2026, Verdiva Bio Dev estimated primary completion of a Phase 2 trial in obesity, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07553299 | |
| Clinical | Zhejiang Wenda Pharma Technology | As of 29 June 2026, Zhejiang Wenda Pharma Technology estimated primary completion of a Phase 3 trial in Moderate to Severe Plaque Psoriasis, on 30 November 2026. | Estimated | ClinicalTrials.gov registration: NCT07672561 | |
| Clinical | 3D Medicines (Sichuan) Co. | As of 25 March 2026, 3D Medicines (Sichuan) Co. estimated primary completion of a Phase 2 trial in Advanced Endometrial Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05112991 | |
| Clinical | 3D Medicines (Sichuan) Co. | As of 25 March 2026, 3D Medicines (Sichuan) Co. estimated primary completion of a Phase 2 trial in Solid Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05024214 | |
| Clinical | 858 Therapeutics | As of 27 March 2026, 858 Therapeutics estimated primary completion of a Phase 2 trial in Advanced or Metastatic Solid Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06395519 | |
| Clinical | A2 Biotherapeutics | As of 25 April 2025, A2 Biotherapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05736731 | |
| Clinical | AP Biosciences | As of 25 April 2025, AP Biosciences estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06669975 | |
| Clinical | AP Biosciences | As of 26 March 2025, AP Biosciences estimated primary completion of a Phase 2 trial in Locally Advanced or Metastatic Solid Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05473156 | |
| Clinical | ASTEROGENE Biomedical Co. | As of 3 April 2026, ASTEROGENE Biomedical Co. estimated primary completion of a Phase 2 trial in Intervertebral Disc Degeneration, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07168603 | |
| Clinical | Aadi Bioscience | As of 13 November 2025, Aadi Bioscience estimated primary completion of a Phase 2 trial in Endometrial Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05997017 | |
| Clinical | AbbVie | As of 28 April 2026, AbbVie estimated primary completion of a Phase 3 trial in aMD, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04704921 | |
| Clinical | AbbVie | As of 19 September 2025, AbbVie estimated primary completion of a Phase 2 trial in Irritable Bowel Syndrome, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03339128 | |
| Clinical | AbbVie | As of 2 September 2026, AbbVie estimated primary completion of a Phase 3 trial in Hidradenitis Suppurativa, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06468228 | |
| Clinical | AbbVie | As of 12 December 2025, AbbVie estimated primary completion of a Phase 2 trial in Unresectable Metastatic Colorectal Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06107413 | |
| Clinical | Abivax | As of 27 April 2026, Abivax estimated primary completion of a Phase 2 trial in Moderately to Severely Active Crohn Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06456593 | |
| Clinical | Adicet Therapeutics | As of 10 September 2026, Adicet Therapeutics estimated primary completion of a Phase 2 trial in Clear Cell Renal Cell Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06480565 | |
| Clinical | Akeso | As of 16 March 2026, Akeso estimated primary completion of a Phase 3 trial in Triple-Negative Breast Cancer (TNBC), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06767527 | |
| Clinical | Akeso | As of 18 March 2026, Akeso estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05689853 | |
| Clinical | Akeso | As of 3 June 2025, Akeso estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer Stage IIIB/IV, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06943820 | |
| Clinical | Aldeyra Therapeutics | As of 11 February 2026, Aldeyra Therapeutics estimated primary completion of a Phase 3 trial in Primary Vitreoretinal Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07402876 | |
| Clinical | Alkeus Pharmaceuticals | As of 27 April 2025, Alkeus Pharmaceuticals estimated primary completion of a Phase 2 trial in Stargardt Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04239625 | |
| Clinical | Allist Pharmaceuticals | As of 13 August 2026, Allist Pharmaceuticals estimated primary completion of a Phase 3 trial in Non-small Cell Lung Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04853342 | |
| Clinical | Alto Neuroscience | As of 24 July 2025, Alto Neuroscience estimated primary completion of a Phase 2 trial in Major Depressive Disorder, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05922878 | |
| Clinical | Alyssum Therapeutics | As of 23 July 2026, Alyssum Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06234098 | |
| Clinical | Alzamend Neuro | As of 28 July 2026, Alzamend Neuro estimated primary completion of a Phase 2 trial in Bipolar I Disorder, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07540338 | |
| Clinical | Ambrx | As of 9 March 2026, Ambrx estimated primary completion of a Phase 2 trial in HER2 Positive Metastatic Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04829604 | |
| Clinical | Amydis | As of 13 February 2026, Amydis estimated primary completion of a Phase 2 trial in Cerebral Amyloid Angiopathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05709314 | |
| Clinical | Angitia Biopharmaceuticals | As of 10 February 2026, Angitia Biopharmaceuticals estimated primary completion of a Phase 2 trial in Postmenopausal Osteoporosis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06577935 | |
| Clinical | Ascentage Pharma Group | As of 27 March 2026, Ascentage Pharma Group estimated primary completion of a Phase 2 trial in Chronic Lymphocytic Leukemia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05147467 | |
| Clinical | Astria Therapeutics | As of 30 June 2026, Astria Therapeutics estimated primary completion of a Phase 3 trial in Hereditary Angioedema (HAE), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06842823 | |
| Clinical | Atea Pharmaceuticals | As of 29 June 2026, Atea Pharmaceuticals estimated primary completion of a Phase 3 trial in HEPATITIS C VIRUS CHRONIC INFECTION, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07037277 | |
| Clinical | Avalyn Pharma | As of 10 August 2026, Avalyn Pharma estimated primary completion of a Phase 2 trial in Idiopathic Pulmonary Fibrosis (IPF), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07194382 | |
| Clinical | Aveta Biomics | As of 16 January 2026, Aveta Biomics estimated primary completion of a Phase 2 trial in Head and Neck Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05312710 | |
| Clinical | Axsome Therapeutics | As of 24 July 2026, Axsome Therapeutics estimated primary completion of a Phase 3 trial in Excessive Sleepiness, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06568367 | |
| Clinical | Axsome Therapeutics | As of 28 July 2026, Axsome Therapeutics estimated primary completion of a Phase 3 trial in Binge-Eating Disorder, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06413433 | |
| Clinical | Beam Therapeutics | As of 13 January 2025, Beam Therapeutics estimated primary completion of a Phase 2 trial in Lymphoblastic Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05885464 | |
| Clinical | Beijing Scitech-Mq Pharmaceuticals | As of 24 August 2025, Beijing Scitech-Mq Pharmaceuticals estimated primary completion of a Phase 2 trial in Unresectable or Metastatic Melanoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06359860 | |
| Clinical | BioCardia | As of 12 December 2025, BioCardia estimated primary completion of a Phase 2 trial in Heart Failure, Systolic, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05925608 | |
| Clinical | BioRestorative Therapies | As of 26 August 2025, BioRestorative Therapies estimated primary completion of a Phase 2 trial in Lumbar Disc Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04042844 | |
| Clinical | Biocomposites | As of 6 May 2026, Biocomposites estimated primary completion of a Phase 2 trial in Pressure Ulcer, Stage IV, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06283979 | |
| Clinical | Biogen | As of 5 June 2026, Biogen estimated primary completion of a Phase 3 trial in Antibody-mediated Rejection, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06685757 | |
| Clinical | Biohaven Therapeutics | As of 24 August 2026, Biohaven Therapeutics estimated primary completion of a Phase 3 trial in Focal Epilepsy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06132893 | |
| Clinical | Biohaven Therapeutics | As of 1 May 2026, Biohaven Therapeutics estimated primary completion of a Phase 2 trial in Focal Epilepsy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06443463 | |
| Clinical | Brii Biosciences | As of 30 December 2024, Brii Biosciences estimated primary completion of a Phase 2 trial in For Treatment of Chronic Hepatitis B Virus Infection, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06491563 | |
| Clinical | COUR Pharmaceutical Development Company | As of 11 September 2026, COUR Pharmaceutical Development Company estimated primary completion of a Phase 2 trial in Type 1 Diabetes Mellitus, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06783309 | |
| Clinical | Cancer Vaccines | As of 20 January 2026, Cancer Vaccines estimated primary completion of a Phase 2 trial in cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03096093 | |
| Clinical | Cartesian Therapeutics | As of 27 March 2026, Cartesian Therapeutics estimated primary completion of a Phase 2 trial in Systemic Lupus Erythematosus (SLE), on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06038474 | |
| Clinical | CellARTs | As of 24 February 2025, CellARTs estimated primary completion of a Phase 2 trial in Infertility, Male, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06841861 | |
| Clinical | Celltrion | As of 11 August 2025, Celltrion estimated primary completion of a Phase 3 trial in t2DM, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07093476 | |
| Clinical | Centessa Pharmaceuticals (UK) | As of 27 April 2026, Centessa Pharmaceuticals (UK) estimated primary completion of a Phase 2 trial in Narcolepsy Type 1, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06752668 | |
| Clinical | Chengdu Kangnuoxing Biopharma | As of 3 September 2026, Chengdu Kangnuoxing Biopharma estimated primary completion of a Phase 3 trial in Seasonal Allergic Rhinitis (SAR), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07678931 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 11 March 2026, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Biliary Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05987358 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 17 April 2026, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05780567 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 12 March 2024, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06202261 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 8 December 2025, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in myelofibrosis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06122831 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Co. | As of 20 February 2025, Chia Tai Tianqing Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Advanced Hepatocellular Carcinoma (HCC), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04344158 | |
| Clinical | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. | As of 26 August 2024, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-alcoholic Steatohepatitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06569524 | |
| Clinical | CivaTech Oncology | As of 4 April 2025, CivaTech Oncology estimated primary completion of a Phase 2 trial in Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03290534 | |
| Clinical | Compass Therapeutics | As of 7 May 2026, Compass Therapeutics estimated primary completion of a Phase 3 trial in Biliary Tract Cancer, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05506943 | |
| Clinical | Connect Biopharm | As of 27 August 2026, Connect Biopharm estimated primary completion of a Phase 2 trial in Asthma Acute, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07705737 | |
| Clinical | Cook MyoSite | As of 21 July 2026, Cook MyoSite estimated primary completion of a Phase 3 trial in Fecal Incontinence, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05776277 | |
| Clinical | Corcept Therapeutics | As of 25 August 2026, Corcept Therapeutics estimated primary completion of a Phase 2 trial in Cushing Syndrome, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03604198 | |
| Clinical | Delcath Systems | As of 1 June 2026, Delcath Systems estimated primary completion of a Phase 2 trial in Refractory Metastatic Colorectal Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06607458 | |
| Clinical | Denali Therapeutics | As of 15 January 2026, Denali Therapeutics estimated primary completion of a Phase 2 trial in Frontotemporal Dementia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05262023 | |
| Clinical | Design Therapeutics | As of 18 May 2025, Design Therapeutics estimated primary completion of a Phase 2 trial in Friedreich Ataxia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06874010 | |
| Clinical | DiaMedica Therapeutics | As of 21 August 2026, DiaMedica Therapeutics estimated primary completion of a Phase 3 trial in Acute Stroke, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05065216 | |
| Clinical | Dianthus Therapeutics | As of 10 August 2026, Dianthus Therapeutics estimated primary completion of a Phase 2 trial in Multifocal Motor Neuropathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06537999 | |
| Clinical | Dizal Pharmaceuticals | As of 31 December 2025, Dizal Pharmaceuticals estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06295432 | |
| Clinical | Dr. Falk Pharma | As of 28 August 2026, Dr. Falk Pharma estimated primary completion of a Phase 3 trial in Eosinophilic Esophagitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06596252 | |
| Clinical | Dren Bio | As of 17 June 2026, Dren Bio estimated primary completion of a Phase 2 trial in LGLL - Large Granular Lymphocytic Leukemia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05475925 | |
| Clinical | EicOsis Human Health | As of 10 July 2026, EicOsis Human Health estimated primary completion of a Phase 2 trial in Parkinson's Disease (PD), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07142044 | |
| Clinical | Eikon Therapeutics | As of 28 May 2026, Eikon Therapeutics estimated primary completion of a Phase 2 trial in nSCLC, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06246110 | |
| Clinical | Eli Lilly and | As of 21 August 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in Type 2 Diabetes, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06897475 | |
| Clinical | Eli Lilly and | As of 4 September 2026, Eli Lilly and estimated primary completion of a Phase 2 trial in nausea, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07169851 | |
| Clinical | Elion Therapeutics | As of 3 September 2026, Elion Therapeutics estimated primary completion of a Phase 2 trial in Invasive Mould Infection, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07215273 | |
| Clinical | Elixiron Immunotherapeutics | As of 9 June 2026, Elixiron Immunotherapeutics estimated primary completion of a Phase 2 trial in Mild, Moderate, or Severe Alzheimer's Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06745583 | |
| Clinical | Enanta Pharmaceuticals | As of 20 July 2026, Enanta Pharmaceuticals estimated primary completion of a Phase 2 trial in RSV Infection, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07482657 | |
| Clinical | Enveda Therapeutics | As of 29 July 2026, Enveda Therapeutics estimated primary completion of a Phase 2 trial in asthma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07301255 | |
| Clinical | Enveda Therapeutics | As of 29 July 2026, Enveda Therapeutics estimated primary completion of a Phase 2 trial in Atopic Dermatitis (AD), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07298395 | |
| Clinical | EpicentRx | As of 26 June 2026, EpicentRx estimated primary completion of a Phase 2 trial in Solid Tumor, Adult, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04673942 | |
| Clinical | Eupraxia Pharmaceuticals | As of 19 March 2026, Eupraxia Pharmaceuticals estimated primary completion of a Phase 2 trial in Eosinophilic Esophagitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05608681 | |
| Clinical | FindCure Biosciences (ZhongShan) Co. | As of 4 September 2026, FindCure Biosciences (ZhongShan) Co. estimated primary completion of a Phase 2 trial in Advanced Malignant Solid Tumors, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06499350 | |
| Clinical | Frantz Viral Therapeutics | As of 14 August 2025, Frantz Viral Therapeutics estimated primary completion of a Phase 2 trial in Vulvar Diseases, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06075264 | |
| Clinical | Fujian Akeylink Biotechnology Co. | As of 23 January 2026, Fujian Akeylink Biotechnology Co. estimated primary completion of a Phase 3 trial in Chronic Hepatitis b, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07090759 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 31 July 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Mild to Moderate Hypertension, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07297797 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 26 August 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Prevention of Postoperative Nausea and Vomiting, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07709897 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 26 January 2026, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06994650 | |
| Clinical | Fujian Shengdi Pharmaceutical Co. | As of 17 November 2025, Fujian Shengdi Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Bstructive Sleep Apnea (OSA) and Obesity, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06974851 | |
| Clinical | GC Cell | As of 22 November 2021, GC Cell estimated primary completion of a Phase 3 trial in Pancreatic Ductal Adenocarcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04969731 | |
| Clinical | GE Healthcare | As of 6 May 2026, GE Healthcare estimated primary completion of a Phase 2 trial in Myocardial Ischemia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04604782 | |
| Clinical | Galderma R&D | As of 27 July 2026, Galderma R&D estimated primary completion of a Phase 2 trial in Chronic Pruritus of Unknown Origin, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07074977 | |
| Clinical | GeneCradle | As of 3 July 2025, GeneCradle estimated primary completion of a Phase 2 trial in Pompe Disease (Late-onset), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06391736 | |
| Clinical | GeneCradle | As of 3 July 2025, GeneCradle estimated primary completion of a Phase 2 trial in Spinal Muscular Atrophy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05824169 | |
| Clinical | GeneCradle | As of 3 July 2025, GeneCradle estimated primary completion of a Phase 2 trial in Spinal Muscular Atrophy Type 3, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06421831 | |
| Clinical | Genelux | As of 26 August 2026, Genelux estimated primary completion of a Phase 3 trial in Platinum-resistant Ovarian Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05281471 | |
| Clinical | Georgiamune | As of 14 August 2026, Georgiamune estimated primary completion of a Phase 2 trial in Melanoma Stage IV, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06425926 | |
| Clinical | Gilead Sciences | As of 9 February 2026, Gilead Sciences estimated primary completion of a Phase 3 trial in Metastatic Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04639986 | |
| Clinical | Gossamer Bio USA | As of 29 July 2026, Gossamer Bio USA estimated primary completion of a Phase 3 trial in Pulmonary Arterial Hypertension, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06274801 | |
| Clinical | Grand Shuyang Life Sciences (Chengdu) Co. | As of 8 April 2026, Grand Shuyang Life Sciences (Chengdu) Co. estimated primary completion of a Phase 3 trial in Primary Immune Thrombocytopenia (ITP), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07233213 | |
| Clinical | Guangdong Hengrui Pharmaceutical Co. | As of 17 August 2026, Guangdong Hengrui Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Seasonal Allergic Rhinitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07688772 | |
| Clinical | Guangzhou Gloria Biosciences Co. | As of 18 June 2023, Guangzhou Gloria Biosciences Co. estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05909436 | |
| Clinical | Henan Genuine Biotech Co. | As of 6 January 2026, Henan Genuine Biotech Co. estimated primary completion of a Phase 2 trial in HIV-1 Infection, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07308782 | |
| Clinical | Heron Neutron Medical | As of 9 July 2026, Heron Neutron Medical estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07691775 | |
| Clinical | Imbria Pharmaceuticals | As of 18 May 2026, Imbria Pharmaceuticals estimated primary completion of a Phase 2 trial in Non-obstructive Hypertrophic Cardiomyopathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07023614 | |
| Clinical | Inmunotek S.L. | As of 13 May 2025, Inmunotek S.L. estimated primary completion of a Phase 3 trial in Rhinitis, Allergic, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04435990 | |
| Clinical | Institut de Recherches Internationales Servier | As of 25 February 2026, Institut de Recherches Internationales Servier estimated primary completion of a Phase 2 trial in ALL, Adult, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06052813 | |
| Clinical | Intra-IMMUSG Pte | As of 22 April 2026, Intra-IMMUSG Pte estimated primary completion of a Phase 2 trial in Solid Tumor, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04452955 | |
| Clinical | Intra-IMMUSG Pte | As of 16 April 2026, Intra-IMMUSG Pte estimated primary completion of a Phase 3 trial in Advanced Solid Cancers, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07290088 | |
| Clinical | Ionis Pharmaceuticals | As of 12 December 2025, Ionis Pharmaceuticals estimated primary completion of a Phase 3 trial in Hereditary Angioedema, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05392114 | |
| Clinical | Iperboreal Pharma Srl | As of 16 May 2025, Iperboreal Pharma Srl estimated primary completion of a Phase 2 trial in Congestive Heart Failure, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03994874 | |
| Clinical | Italfarma | As of 30 April 2025, Italfarma estimated primary completion of a Phase 2 trial in Chronic Myeloproliferative Neoplasms, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT01761968 | |
| Clinical | JYAMS PET Research & Development | As of 20 February 2026, JYAMS PET Research & Development estimated primary completion of a Phase 3 trial on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07422857 | |
| Clinical | Janssen Research & Development | As of 28 August 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Prostatic Neoplasms, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03767244 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 12 June 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06974929 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 4 June 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Diabetes Mellitus, Type 2, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07472725 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 19 May 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in Advanced Gastroenteropancreatic Neuroendocrine Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05884255 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 20 April 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 2 trial in Advanced Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05482568 | |
| Clinical | Jiangsu HengRui Medicine Co. | As of 17 July 2026, Jiangsu HengRui Medicine Co. estimated primary completion of a Phase 3 trial in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06507436 | |
| Clinical | K-Group, Beta | As of 1 July 2026, K-Group, Beta estimated primary completion of a Phase 2 trial on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05128825 | |
| Clinical | Kardigan | As of 2 September 2026, Kardigan estimated primary completion of a Phase 2 trial in hypertension, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07511361 | |
| Clinical | Karyopharm Therapeutics | As of 2 July 2026, Karyopharm Therapeutics estimated primary completion of a Phase 3 trial in Relapsed/Refractory Diffuse Large B-cell Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04442022 | |
| Clinical | Karyopharm Therapeutics | As of 2 July 2026, Karyopharm Therapeutics estimated primary completion of a Phase 2 trial in Diffuse Large B-cell Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT02227251 | |
| Clinical | Kedrion S.p.A. | As of 11 September 2026, Kedrion S.p.A. estimated primary completion of a Phase 3 trial in Chronic Primary Immune Thrombocytopenia (ITP), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07059000 | |
| Clinical | Kedrion S.p.A. | As of 29 May 2026, Kedrion S.p.A. estimated primary completion of a Phase 3 trial in Primary Immunodeficiency Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04944979 | |
| Clinical | Keymed Biosciences Co. | As of 15 October 2024, Keymed Biosciences Co. estimated primary completion of a Phase 2 trial in Multiple Myeloma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05299424 | |
| Clinical | Kind Pharmaceuticals | As of 27 March 2026, Kind Pharmaceuticals estimated primary completion of a Phase 3 trial in Anemia Due to Chronic Kidney Disease, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07487727 | |
| Clinical | Kind Pharmaceuticals | As of 27 February 2026, Kind Pharmaceuticals estimated primary completion of a Phase 2 trial in Myelodysplastic Syndromes, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06304103 | |
| Clinical | Kind Pharmaceuticals | As of 27 February 2026, Kind Pharmaceuticals estimated primary completion of a Phase 2 trial in β -Thalassemia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06302491 | |
| Clinical | Kite, A Gilead | As of 11 February 2026, Kite, A Gilead estimated primary completion of a Phase 2 trial in Multiple Myeloma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05396885 | |
| Clinical | Krystal Biotech | As of 27 February 2026, Krystal Biotech estimated primary completion of a Phase 2 trial in Neurotrophic Keratitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06999733 | |
| Clinical | Krystal Biotech | As of 12 March 2026, Krystal Biotech estimated primary completion of a Phase 3 trial in Dystrophic Epidermolysis Bullosa, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07016750 | |
| Clinical | LaNova Medicines | As of 2 May 2025, LaNova Medicines estimated primary completion of a Phase 2 trial in Malignant Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06650566 | |
| Clinical | Lamassu Bio | As of 9 September 2026, Lamassu Bio estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06578624 | |
| Clinical | Lantern Pharma | As of 4 May 2026, Lantern Pharma estimated primary completion of a Phase 2 trial in Adenocarcinoma of Lung, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05456256 | |
| Clinical | Latticon Antibody Therapeutics | As of 8 July 2025, Latticon Antibody Therapeutics estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06277219 | |
| Clinical | Lexeo Therapeutics | As of 12 November 2025, Lexeo Therapeutics estimated primary completion of a Phase 2 trial in Arrhythmogenic Cardiomyopathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06109181 | |
| Clinical | Lumicell | As of 16 January 2026, Lumicell estimated primary completion of a Phase 2 trial in Colorectal Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT02584244 | |
| Clinical | Luxa Biotechnology | As of 15 October 2025, Luxa Biotechnology estimated primary completion of a Phase 2 trial in Dry Age-related Macular Degeneration, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04627428 | |
| Clinical | Mabscale | As of 16 August 2024, Mabscale estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05654454 | |
| Clinical | Mabwell (Shanghai) Bioscience Co. | As of 8 May 2026, Mabwell (Shanghai) Bioscience Co. estimated primary completion of a Phase 2 trial in scar, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07576608 | |
| Clinical | Madrigal Pharmaceuticals | As of 8 July 2026, Madrigal Pharmaceuticals estimated primary completion of a Phase 3 trial in nASH, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05500222 | |
| Clinical | MediWound | As of 24 August 2026, MediWound estimated primary completion of a Phase 3 trial in Venous Leg Ulcer (VLU), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06568627 | |
| Clinical | Meribank Biotech Co. | As of 15 July 2024, Meribank Biotech Co. estimated primary completion of a Phase 2 trial in Pathologic Processes, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06501066 | |
| Clinical | Minovia Therapeutics | As of 22 June 2025, Minovia Therapeutics estimated primary completion of a Phase 2 trial in Mitochondrial Diseases, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06017869 | |
| Clinical | NKGen Biotech | As of 2 July 2026, NKGen Biotech estimated primary completion of a Phase 2 trial in Moderate Alzheimer Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06189963 | |
| Clinical | NMD Pharma | As of 21 August 2026, NMD Pharma estimated primary completion of a Phase 2 trial in Myasthenia Gravis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06414954 | |
| Clinical | NS Pharma | As of 26 May 2026, NS Pharma estimated primary completion of a Phase 2 trial in Eosinophilic Granulomatosis With Polyangiitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06046222 | |
| Clinical | Nanjing Leads Biolabs Co. | As of 30 June 2026, Nanjing Leads Biolabs Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05170958 | |
| Clinical | Napo Pharmaceuticals | As of 9 June 2026, Napo Pharmaceuticals estimated primary completion of a Phase 3 trial in Microvillus Inclusion Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06721871 | |
| Clinical | Newsoara HYK Biopharmaceutical (Shanghai) Co. | As of 3 December 2025, Newsoara HYK Biopharmaceutical (Shanghai) Co. estimated primary completion of a Phase 2 trial in SCLC, Extensive Stage, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07136285 | |
| Clinical | Nexcella | As of 14 July 2026, Nexcella estimated primary completion of a Phase 2 trial in Light Chain (AL) Amyloidosis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06097832 | |
| Clinical | NoNO | As of 15 July 2025, NoNO estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06403267 | |
| Clinical | Octapharma | As of 6 August 2026, Octapharma estimated primary completion of a Phase 3 trial in Acute Hereditary Angio Edema, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06361537 | |
| Clinical | Octapharma | As of 3 June 2026, Octapharma estimated primary completion of a Phase 3 trial in Congenital Antithrombin Deficiency, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04918173 | |
| Clinical | Oculis | As of 28 August 2026, Oculis estimated primary completion of a Phase 3 trial in Dry Eye Disease (DED), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07548632 | |
| Clinical | Omeros | As of 16 July 2026, Omeros estimated primary completion of a Phase 2 trial in Paroxysmal Nocturnal Hemoglobinuria, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06298955 | |
| Clinical | One-carbon Therapeutics | As of 28 January 2026, One-carbon Therapeutics estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07151040 | |
| Clinical | OriCell Therapeutics Co. | As of 3 April 2024, OriCell Therapeutics Co. estimated primary completion of a Phase 2 trial in Hepatocellular Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05652920 | |
| Clinical | PT. Prodia Stem Cell Indonesia | As of 27 February 2026, PT. Prodia Stem Cell Indonesia estimated primary completion of a Phase 2 trial in Acute Respiratory Distress Syndrome, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07439848 | |
| Clinical | Pacira Pharmaceuticals | As of 29 May 2026, Pacira Pharmaceuticals estimated primary completion of a Phase 3 trial in Glenohumeral Osteoarthritis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06269705 | |
| Clinical | Panafina | As of 5 August 2026, Panafina estimated primary completion of a Phase 2 trial in Acute Pancreatitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06080789 | |
| Clinical | Phoenix Molecular Designs | As of 16 July 2026, Phoenix Molecular Designs estimated primary completion of a Phase 2 trial in Metastatic Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04115306 | |
| Clinical | Praxis Precision Medicines | As of 3 August 2026, Praxis Precision Medicines estimated primary completion of a Phase 3 trial in Epileptic Encephalopathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07019922 | |
| Clinical | Praxis Precision Medicines | As of 4 August 2026, Praxis Precision Medicines estimated primary completion of a Phase 3 trial in Developmental and Epileptic Encephalopathy 1, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07010471 | |
| Clinical | Priovant Therapeutics | As of 18 May 2025, Priovant Therapeutics estimated primary completion of a Phase 2 trial in Cutaneous Sarcoidosis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06978725 | |
| Clinical | Protara Therapeutics | As of 24 August 2026, Protara Therapeutics estimated primary completion of a Phase 2 trial in Lymphatic Malformation, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05871970 | |
| Clinical | Pulmovant | As of 2 September 2026, Pulmovant estimated primary completion of a Phase 2 trial in Pulmonary Hypertension, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07333183 | |
| Clinical | Pulmovant | As of 20 February 2026, Pulmovant estimated primary completion of a Phase 2 trial in Pulmonary Hypertension, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06635850 | |
| Clinical | Qilu Pharmaceutical Co. | As of 10 June 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in nSCLC, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06754644 | |
| Clinical | Qilu Pharmaceutical Co. | As of 30 July 2025, Qilu Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Hospital-acquired Bacterial Pneumonia (HABP), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07089186 | |
| Clinical | Qilu Pharmaceutical Co. | As of 22 May 2026, Qilu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in hypertension (HTN), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07489612 | |
| Clinical | Qilu Pharmaceutical Co. | As of 2 June 2026, Qilu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Advanced Prostate Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07198633 | |
| Clinical | RDC Clinical Pty | As of 2 July 2026, RDC Clinical Pty estimated primary completion of a Phase 3 trial in Absorption of Omega-3, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07241377 | |
| Clinical | Ranok Therapeutics (Hangzhou) Co. | As of 30 October 2025, Ranok Therapeutics (Hangzhou) Co. estimated primary completion of a Phase 2 trial in KRAS G12D Mutation, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06667544 | |
| Clinical | RayzeBio | As of 30 March 2026, RayzeBio estimated primary completion of a Phase 3 trial in gEP-NET, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05477576 | |
| Clinical | ReAlta Life Sciences | As of 13 April 2026, ReAlta Life Sciences estimated primary completion of a Phase 2 trial in Hypoxic-Ischemic Encephalopathy, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05778188 | |
| Clinical | ReAlta Life Sciences | As of 24 November 2025, ReAlta Life Sciences estimated primary completion of a Phase 2 trial in Steroid Refractory GVHD, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06343792 | |
| Clinical | Red de Terapia Celular | As of 24 July 2025, Red de Terapia Celular estimated primary completion of a Phase 2 trial in Lupus Nephritis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03673748 | |
| Clinical | Regenerative Ocular Immunobiologics | As of 8 July 2026, Regenerative Ocular Immunobiologics estimated primary completion of a Phase 2 trial in oGHVD, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06852768 | |
| Clinical | RemeGen Co. | As of 3 April 2024, RemeGen Co. estimated primary completion of a Phase 3 trial in Gastric Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06221748 | |
| Clinical | Resolve Therapeutics | As of 18 July 2025, Resolve Therapeutics estimated primary completion of a Phase 2 trial in Primary Sjögren Syndrome, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06440525 | |
| Clinical | Rottapharm Biotech | As of 29 October 2025, Rottapharm Biotech estimated primary completion of a Phase 2 trial in Refractory Metastatic Colorectal Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05205330 | |
| Clinical | Ryvu Therapeutics SA | As of 29 September 2025, Ryvu Therapeutics SA estimated primary completion of a Phase 2 trial in Non-Hodgkin Lymphoma, B-cell, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06534437 | |
| Clinical | Ryvu Therapeutics SA | As of 11 September 2026, Ryvu Therapeutics SA estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06987058 | |
| Clinical | SERDA bv | As of 7 August 2026, SERDA bv estimated primary completion of a Phase 2 trial in Burn Injury, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06628037 | |
| Clinical | Sanofi | As of 16 January 2026, Sanofi estimated primary completion of a Phase 2 trial in Pandemic Influenza Immunization, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06907511 | |
| Clinical | Sanofi | As of 18 May 2026, Sanofi estimated primary completion of a Phase 3 trial in Chronic Obstructive Pulmonary Disease, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06208306 | |
| Clinical | Sanofi Pasteur, a Sanofi | As of 6 October 2025, Sanofi Pasteur, a Sanofi estimated primary completion of a Phase 3 trial in Pneumococcal Infections, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06838000 | |
| Clinical | Sapience Therapeutics | As of 9 February 2026, Sapience Therapeutics estimated primary completion of a Phase 2 trial in glioblastoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04478279 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 29 December 2025, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06820099 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 26 January 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 3 trial in Locally Advanced Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07024173 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 26 January 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in Advanced Malignant Tumour, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06915142 | |
| Clinical | Shandong Suncadia Medicine Co. | As of 2 June 2026, Shandong Suncadia Medicine Co. estimated primary completion of a Phase 2 trial in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07229950 | |
| Clinical | Shanghai BDgene Co. | As of 18 May 2025, Shanghai BDgene Co. estimated primary completion of a Phase 2 trial in Herpes Simplex Virus Type I Stromal Keratitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06474442 | |
| Clinical | Shanghai Fosun Pharmaceutical Industrial Development Co. | As of 5 March 2025, Shanghai Fosun Pharmaceutical Industrial Development Co. estimated primary completion of a Phase 2 trial in safety, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06858618 | |
| Clinical | Shanghai Pharmaceuticals Holding Co. | As of 14 January 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 3 trial in Locally Advanced or Metastatic Breast Cancer, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05860465 | |
| Clinical | Shanghai Vitalgen BioPharma Co. | As of 24 December 2025, Shanghai Vitalgen BioPharma Co. estimated primary completion of a Phase 3 trial in Bietti Crystalline Dystrophy, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06699108 | |
| Clinical | Shanghai Yidian Pharmaceutical Technology Development Co. | As of 17 February 2026, Shanghai Yidian Pharmaceutical Technology Development Co. estimated primary completion of a Phase 2 trial in sepsis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07413094 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 17 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06500026 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06114511 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 8 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Her2-positive/Low-expression Urinary and Digestive Tract Tumors, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06031584 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05924841 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Gynecological Malignant Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05803018 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Urinary System Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05785039 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Urothelial Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06405425 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Esophageal Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06008054 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-hodgkin's Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05623982 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Gynecological Malignancies, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06131450 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Urothelial Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05965856 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Head and Neck Squamous Cell Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06006169 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06042894 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Extensive-stage Small-cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06437509 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 27 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-hodgkin's Lymphoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06066203 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 28 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Squamous Cell Carcinoma of Head and Neck, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05668858 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Cervical Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05990803 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 23 July 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Triple-negative Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06471205 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 17 April 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06382129 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 1 September 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Head and Neck Squamous Cell Carcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05054439 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 26 September 2025, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05956587 | |
| Clinical | Sichuan Baili Pharmaceutical Co. | As of 28 August 2026, Sichuan Baili Pharmaceutical Co. estimated primary completion of a Phase 2 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05949606 | |
| Clinical | Sichuan Huiyu Pharmaceutical Co. | As of 29 January 2026, Sichuan Huiyu Pharmaceutical Co. estimated primary completion of a Phase 2 trial in safety, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06243354 | |
| Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co. | As of 8 July 2026, Sichuan Kelun-Biotech Biopharmaceutical Co. estimated primary completion of a Phase 3 trial in Non-Small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06711900 | |
| Clinical | Sinew Pharma | As of 10 January 2024, Sinew Pharma estimated primary completion of a Phase 2 trial in hepatitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05557448 | |
| Clinical | Songqi Gao | As of 19 December 2025, Songqi Gao estimated primary completion of a Phase 2 trial in MRI Scan, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06262139 | |
| Clinical | Sound Pharmaceuticals, Incorporated | As of 13 July 2026, Sound Pharmaceuticals, Incorporated estimated primary completion of a Phase 3 trial in Meniere's Disease, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06859788 | |
| Clinical | Sound Pharmaceuticals, Incorporated | As of 26 June 2026, Sound Pharmaceuticals, Incorporated estimated primary completion of a Phase 2 trial in Hearing Loss, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06340633 | |
| Clinical | Stemline Therapeutics | As of 9 September 2026, Stemline Therapeutics estimated primary completion of a Phase 2 trial in Breast Neoplasms, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05386108 | |
| Clinical | Step Pharma | As of 16 June 2026, Step Pharma estimated primary completion of a Phase 2 trial in Lymphoma, B-Cell, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05463263 | |
| Clinical | Sunhawk Vision Biotech | As of 23 January 2026, Sunhawk Vision Biotech estimated primary completion of a Phase 2 trial in Myopia, Progressive, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06579287 | |
| Clinical | Sunshine Lake Pharma Co. | As of 24 April 2026, Sunshine Lake Pharma Co. estimated primary completion of a Phase 2 trial in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05139719 | |
| Clinical | Suven Life Sciences | As of 12 January 2026, Suven Life Sciences estimated primary completion of a Phase 3 trial in agitation, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05397639 | |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 19 March 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 3 trial in Non-small Cell Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06671379 | |
| Moved from 31 Aug 2026 | Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 8 September 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in nSCLC, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06844474 |
| Clinical | Suzhou Suncadia Biopharmaceuticals Co. | As of 11 September 2026, Suzhou Suncadia Biopharmaceuticals Co. estimated primary completion of a Phase 2 trial in Ovarian Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06840002 | |
| Clinical | SynDevRx | As of 22 April 2026, SynDevRx estimated primary completion of a Phase 2 trial in HR+/HER2-negative Breast Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05455619 | |
| Clinical | SynerGene Therapeutics | As of 30 May 2025, SynerGene Therapeutics estimated primary completion of a Phase 2 trial in Metastatic Pancreatic Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT02340117 | |
| Clinical | TBF Genie Tissulaire | As of 30 September 2025, TBF Genie Tissulaire estimated primary completion of a Phase 2 trial in Osteoarthritis Hand, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06038331 | |
| Clinical | TR Therapeutics | As of 2 April 2025, TR Therapeutics estimated primary completion of a Phase 3 trial in Venous Leg Ulcer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06707103 | |
| Clinical | TVAX Biomedical | As of 1 July 2025, TVAX Biomedical estimated primary completion of a Phase 3 trial in Glioblastoma Multiforme of Brain, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05685004 | |
| Clinical | Taiho Oncology | As of 1 September 2026, Taiho Oncology estimated primary completion of a Phase 2 trial in Advanced Cholangiocarcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05727176 | |
| Clinical | Tasly Pharmaceutical Group Co. | As of 21 November 2024, Tasly Pharmaceutical Group Co. estimated primary completion of a Phase 3 trial in Ankylosing Spondylitis, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06000956 | |
| Clinical | Tasly Pharmaceuticals | As of 9 April 2025, Tasly Pharmaceuticals estimated primary completion of a Phase 3 trial in Chronic Stable Angina Pectoris, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03789552 | |
| Clinical | Technophage, SA | As of 9 September 2025, Technophage, SA estimated primary completion of a Phase 2 trial in Acute Spinal Cord Injury (SCI), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06677229 | |
| Clinical | Theralase® Technologies | As of 24 November 2025, Theralase® Technologies estimated primary completion of a Phase 2 trial in Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03945162 | |
| Clinical | TiumBio Co. | As of 30 March 2025, TiumBio Co. estimated primary completion of a Phase 2 trial in Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05784688 | |
| Clinical | TolerogenixX | As of 11 April 2025, TolerogenixX estimated primary completion of a Phase 2 trial in Kidney Transplantation, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05365672 | |
| Clinical | Toll Biotech Co. | As of 17 February 2026, Toll Biotech Co. estimated primary completion of a Phase 2 trial in Rheumatoid Arthritis (RA), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07408024 | |
| Clinical | TransThera Sciences (Nanjing) | As of 6 July 2026, TransThera Sciences (Nanjing) estimated primary completion of a Phase 3 trial in cholangiocarcinoma, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05948475 | |
| Clinical | Traws Pharma | As of 27 March 2026, Traws Pharma estimated primary completion of a Phase 2 trial in influenza, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07371650 | |
| Clinical | United Therapeutics | As of 20 February 2026, United Therapeutics estimated primary completion of a Phase 3 trial in pAH, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT03683186 | |
| Clinical | VIS | As of 5 September 2024, VIS estimated primary completion of a Phase 3 trial in presbyopia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06487897 | |
| Clinical | Vanda Pharmaceuticals | As of 17 August 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 3 trial in Social Anxiety Disorder (SAD), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07221578 | |
| Clinical | Vanda Pharmaceuticals | As of 20 April 2026, Vanda Pharmaceuticals estimated primary completion of a Phase 3 trial in Nausea and Vomiting, on 1 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07446439 | |
| Clinical | Vantive Health | As of 27 July 2026, Vantive Health estimated primary completion of a Phase 3 trial in Regional Citrate Anticoagulation (RCA), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05399537 | |
| Clinical | VapeAway | As of 7 January 2026, VapeAway estimated primary completion of a Phase 2 trial in Addiction Nicotine, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07322432 | |
| Clinical | Veradermics | As of 12 February 2026, Veradermics estimated primary completion of a Phase 3 trial in Androgenetic Alopecia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06972264 | |
| Clinical | Vergent Bioscience | As of 19 August 2026, Vergent Bioscience estimated primary completion of a Phase 3 trial in Lung Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07499674 | |
| Clinical | Verona Pharma | As of 13 May 2026, Verona Pharma estimated primary completion of a Phase 2 trial in cOPD, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05270525 | |
| Clinical | Vir Biotechnology | As of 13 July 2026, Vir Biotechnology estimated primary completion of a Phase 3 trial in Viral Hepatitis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT07128550 | |
| Clinical | Wuxi Cellular Biopharmaceutical Group | As of 16 July 2025, Wuxi Cellular Biopharmaceutical Group estimated primary completion of a Phase 3 trial in Knee Osteoarthritis, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06570291 | |
| Clinical | Xenothera | As of 20 August 2026, Xenothera estimated primary completion of a Phase 2 trial in Advanced Solid Tumor, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06154291 | |
| Clinical | Zenith Epigenetics | As of 8 May 2026, Zenith Epigenetics estimated primary completion of a Phase 2 trial in Metastatic Castration-Resistant Prostate Cancer, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT04986423 | |
| Clinical | Zhejiang Haichang Biotech Co. | As of 11 September 2026, Zhejiang Haichang Biotech Co. estimated primary completion of a Phase 2 trial in Advanced Hepatocellular Carcinoma (HCC), in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06309485 | |
| Clinical | Zucara Therapeutics | As of 29 April 2026, Zucara Therapeutics estimated primary completion of a Phase 2 trial in Type 1 Diabetes Mellitus With Hypoglycemia, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT05762107 | |
| Clinical | jCyte | As of 30 July 2026, jCyte estimated primary completion of a Phase 2 trial in Retinitis Pigmentosa, in December 2026. | Estimated | ClinicalTrials.gov registration: NCT06912633 | |
| Clinical | Pfizer | As of 26 August 2026, Pfizer estimated primary completion of a Phase 3 trial in Severe Alopecia Areata, on 2 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07029711 | |
| Clinical | Pfizer | As of 24 August 2026, Pfizer estimated primary completion of a Phase 3 trial in Metastatic Castration-Resistant Prostate Cancer, on 2 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06629779 | |
| Clinical | Eisai | As of 11 February 2026, Eisai estimated primary completion of a Phase 2 trial in Alzheimer's Disease, on 3 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06602258 | |
| Clinical | Regeneron Pharmaceuticals | As of 1 July 2026, Regeneron Pharmaceuticals estimated primary completion of a Phase 2 trial in Non-Transfusion Dependent Beta-Thalassemia (NTDT), on 3 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06421636 | |
| Clinical | Pfizer | As of 6 May 2026, Pfizer estimated primary completion of a Phase 3 trial in Lyme Disease, on 4 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07500506 | |
| Clinical | Haisco Pharmaceutical Group Co. | As of 1 June 2026, Haisco Pharmaceutical Group Co. estimated primary completion of a Phase 2 trial in IgA Nephropathy (IgAN), on 5 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07616700 | |
| Clinical | Suzhou Forlong Biotechnology Co. | As of 8 January 2026, Suzhou Forlong Biotechnology Co. estimated primary completion of a Phase 2 trial in Advanced Solid Tumors, on 5 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07131202 |
Week of 7 December 2026
| Date | Lane | Company | Event | Confidence | Source |
|---|---|---|---|---|---|
| Clinical | Alexion Pharmaceuticals | As of 19 December 2025, Alexion Pharmaceuticals estimated primary completion of a Phase 3 trial in nMOSD, on 7 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06724809 | |
| Moved from 31 Oct 2026 | Clinical | Janssen Research & Development | As of 28 August 2026, Janssen Research & Development estimated primary completion of a Phase 3 trial in Atrial Fibrillation, on 8 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05757869 |
| Clinical | Pfizer | As of 1 September 2026, Pfizer estimated primary completion of a Phase 2 trial in Hidradenitis Suppurativa, on 8 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07228390 | |
| Clinical | SK Bioscience Co. | As of 9 September 2026, SK Bioscience Co. estimated primary completion of a Phase 2 trial in Healthy Participants, on 9 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07280858 | |
| Clinical | AstraZeneca | As of 1 September 2026, AstraZeneca estimated primary completion of a Phase 2 trial in Chronic Kidney Disease and Hypertension, on 10 December 2026. | Estimated | ClinicalTrials.gov registration: NCT07222917 | |
| Clinical | Shanghai Pharmaceuticals Holding Co. | As of 30 April 2026, Shanghai Pharmaceuticals Holding Co. estimated primary completion of a Phase 2 trial in Acute Ischemic Stroke, on 10 December 2026. | Estimated | ClinicalTrials.gov registration: NCT05686642 | |
| Clinical | Gan & Lee Pharmaceuticals. | As of 25 November 2025, Gan & Lee Pharmaceuticals. estimated primary completion of a Phase 3 trial in Type 2 Diabetes Mellitus (T2DM), on 11 December 2026. | Estimated | ClinicalTrials.gov registration: NCT06778967 | |
| Clinical | GlaxoSmithKline | As of 18 June 2026, GlaxoSmithKline estimated primary completion of a Phase 2 trial in neoplasms, on 11 December 2026. | Estimated | ClinicalTrials.gov registration: NCT03441113 | |
| Clinical | Seagen | As of 22 July 2026, Seagen estimated primary completion of a Phase 2 trial in Urothelial Carcinoma, on 11 December 2026. | Estimated | ClinicalTrials.gov registration: NCT04879329 |
What this does not cover
The calendar reads government registers and nothing else. It has no view of anything a company has not filed, and no free source publishes pending FDA goal dates, so approval decision dates are absent by construction rather than by omission. An empty week is not evidence that nothing is scheduled that week. Read a gap as a gap in the registers.
Complete response letters are never published here. Neither are live offerings. Both exclusions are deliberate and permanent. The methodology page sets out every source, every gate and the current drop rate.
How it is compiled
Rows are written automatically from primary documents once a day. Nobody reviews each row before it appears. Every sentence is composed from structured fields taken out of the filing, never from the wording of the source, and each one carries the date on which the claim was made so it stays true after a date slips.
Not investment advice
Nothing here is a recommendation to buy or sell anything, and none of it is tailored to any reader. This page is identical for every visitor. It reports what public registers say, and public registers are wrong often enough that you should check the linked document before you act on a row.
Corrections and takedown
Write to calendar@julienwillard.com with the reference identifier of the row. Corrections and takedown requests are answered within two business days. No call is needed and none will be asked for.
When a row changes
A row whose date moves keeps its identity and gains a note saying where it moved from, so a calendar subscription updates the event in place instead of adding a second one. A withdrawn row stays visible for 30 days, struck through, and is listed on the changes page. Nothing disappears without a record.
Citing this page
Willard, J. Biotech catalyst calendar. julienwillard.com/calendar, as of 12 September 2026, 10:04 UTC. Licensed CC BY 4.0.